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CHAPTER 1: MOTIVATIONS FOR IDENTIFYING BIOMARKERS PREDICTIVE OF
EPILEPSY
1.1 Introduction
Epilepsy is a serious neurological disorder that affects 5-10 people out of every 1,000, or
approximately 1% of the global population (Hirtz et al., 2007; Sander, 2003) with an estimated
3% lifetime prevalence (Wyllie, 2001). It is also an ancient disorder, with the earliest references
dating as far back as 2,000 BCE (Magiorkinis, Sidiropoulou, & Diamantis, 2010).

While

advancements in technology and scientific understanding in the last century have enabled
tremendous improvements in the management of epilepsy (Magiorkinis, Diamantis,
Sidiropoulou, & Panteliadis, 2014), relatively little is known about the mechanisms that underlie
seizure generation. Because of this lack in understanding, epilepsy remains a disorder that can
only be diagnosed upon the presenting symptom of recurring seizures and managed primarily
through medication aimed at reducing seizure occurrence but stop short of actually targeting the
underlying causes of the disorder (Cendes, 2012; Loeb, 2011; Temkin, 2009).
To better steer research toward a cure for epilepsy, the updated 2014 NINDS Benchmarks
for Epilepsy Research continues to promote endeavors that seek to understand causes of epilepsy
along with means of preventing epilepsy through the identification of biomarkers as key
priorities for the epilepsy research community ("2014 NINDS Benchmarks for Epilepsy
Research," 2014). Biomarkers that can be used to detect the development of epilepsy prior to
seizure onset, monitor patients for therapeutic efficacy, and inform clinical trials of novel
therapeutics are absolutely crucial to the improvement of epilepsy treatment.
For the management of epilepsy, the first line of defense typically involves the trial of
numerous anti-seizure drugs (ASDs), in an effort to identify the one or two medications that
provide the most therapeutic benefit while balancing side effects and other drug interactions
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(Moshé, Perucca, Ryvlin, & Tomson, 2014). Even though many patients can achieve seizure
freedom by medications alone, more than 30 percent of epilepsy patients experience inadequate
seizure control on anti-seizure drugs (ASDs) (Kwan & Brodie, 2000) and may become
candidates for epilepsy surgery if the seizures are of a focal nature (Engel & Ojemann, 1993).
Accurate and precise localization of seizure onset regions are essential for treatment success,
since failure to accurately and precisely localize these seizure-inducing regions of the brain can
lead to the persistence of seizures after surgery. The spatial resolution and sensitivity of scalp
EEG is generally inadequate for precise seizure localization, which is generally achieved by
using intracranial electrocorticography (ECoG), a highly invasive surgical procedure involving a
craniotomy and placement of electrodes directly onto the brain, in conjunction with a battery of
various imaging studies (Engel, 1993a; Noachtar & Borggraefe, 2009).

Even with such

tremendous efforts, success is not guaranteed, as the reported long-term success rate of epilepsy
surgery is estimated to vary tremendously between 30-85% (Engel, 1993b; Spencer & Huh,
2008). All of these issues point to the critical need for a non-invasive biomarker that can reliably
localize sources of the seizure activity and act as an indicator of disease progression so that early
intervention may be attempted and newer disease changing drug therapies may be tested more
effectively (Engel et al., 2013).
The fact that surgical resections can be curative implies the existence of key differences
between epileptic and non-epileptic tissue in a patient affected by epilepsy. Furthermore, the fact
that these differences manifest clinically as large scale synchronized electrical discharges (e.g.
seizures) implies the existence of some common final pathway within the disorder. In order to
identify and characterize these key differences, previous studies in our laboratory have compared
gene expression profiles of tissues from both epileptic and non-epileptic regions of multiple
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patients and have identified unique differences in the expressions of MAPK signaling and CREB
activation in the superficial layers of the neocortex (Beaumont, Yao, Shah, Kapatos, & Loeb,
2012; Rakhade et al., 2005).

The presence of these robust transcriptional differences are

suggestive of downstream changes in protein and metabolite expression that can be probed using
techniques such as magnetic resonance spectroscopy (MRS), which is ideally suited for such an
application. MRS has the ability to measure multiple biochemical species at once and the
relative ease by which the technique may be translated from pre-clinical to non-invasive clinical
applications makes it unique.

By using this technique, identified biochemical differences

specific to epileptic regions of the brain can be used to develop non-invasive biomarkers of
epileptic activity, addressing an urgent but still unmet need in both epilepsy research and clinical
management of the disorder.
1.2 Interictal epileptiform discharges as a surrogate for epileptic activity
Seizures are formally defined as “the clinical manifestation of an abnormal, excessive,
hyper-synchronous discharge of a population of cortical neurons”.

When seizures occur

repeatedly without external provocation, it becomes epilepsy (Bromfield, Cavazos, & Sirven,
2006; Fisher et al., 2005). However, in between seizure episodes (i.e. interictal), a form of
paroxysmal and abnormally synchronized neuronal discharges called interictal epileptiform
discharges (IEDs1) can also frequently occur.

Intriguingly, IEDs tend to remain relatively

localized with minimal spread and are not generally associated with specific observable
symptoms but appear as spikes or clusters of spikes on EEG. Nonetheless, they are clinically

1

Although the terms “IED” and “interictal spikes”/“spikes” may appear interchangeable in some instances through
out this text, for the purposes of this dissertation, the term “IED” is generally used to refer to the specific
electrophysiological phenomenon, while “spikes” or “interictal spikes” are used to refer to the waveform typically
observed on EEG that corresponds to the occurrence of IEDs.
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useful for the diagnosis of epilepsy and guiding management approaches (Lüders, Engel, &
Munari, 1993; Pillai & Sperling, 2006).
While the exact relationship between IEDs and seizure activity remains to be elucidated,
they often occur in close proximity to each other and surgical removal of both seizure onset and
IED regions tend to produce superior results over the removal of the seizure onset region alone
(Asano et al., 2003; Bautista, Cobbs, Spencer, & Spencer, 1999; Kanazawa, Blume, & Girvin,
1996; Lee, Kim, Jeong, & Chung, 2014). While IEDs are generally perceived as subclinical or
asymptomatic (Gibbs, 1936), they have been demonstrated to disrupt cognitive and neurologic
functions (Aarts, Binnie, Smit, & Wilkins, 1984; Sanchez Fernandez, Loddenkemper,
Galanopoulou, & Moshe, 2015; Schwab, 1939). Suppression of IEDs using lamotragine has
demonstrated beneficial behavioral effects in children with well-controlled epilepsy (Pressler,
Robinson, Wilson, & Binnie, 2005). Animal studies using a kainate model of epilepsy have also
shown that IEDs typically precede the onset of spontaneous recurrent seizures and an increased
number of IEDs during the prodromal phase was positively correlated with earlier onset of
established epilepsy (White et al., 2010). These observations suggest that IEDs may potentially
be used as a predictive biomarker for the development of chronic epilepsy and are worthy of
further study.
Previous works in our laboratory have shown that the frequency and amplitude of IEDs
are strongly correlated to a set of activity-dependent differences in gene expression (Rakhade et
al., 2005), while a similar relationship between gene expression differences and seizure activity
was not found (Rakhade et al., 2007). This set of activity-dependent genes strongly implicate the
pathway involving cAMP response element binding (CREB) protein dependent transcription via
mitogen-activated protein kinase (MAPK) signaling, especially in the superficial layers II/III of
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the neocortex both in humans (Beaumont et al.,

Original insult

2012) and in a rat model of epilepsy (Barkmeier et
MAPK/CREB activation

Seizures

al., 2012). Collectively, these findings suggest that

Transcriptional changes
Neuronal plasticity

IEDs

IEDs may play a key role in generating or
maintaining an epileptic focus in a MAPK-CREB

Hyperexcitability

Figure 1.1 A theoretical framework for
conceptualizing
the
interactions
between molecular responses to insult,
IEDs, seizures, and the self-reinforcing
nature of epilepsy.

dependent manner (Figure 1.1).

Furthermore,

because IEDs typically occur more frequently than
seizures, they can potentially serve as a sensitive
marker of epileptogenesis, capable of reflecting

epileptogenic changes prior to the establishment of epilepsy (Engel et al., 2013).
1.3 1H Magnetic resonance spectroscopy as a tool for biomarker detection
The very fact that surgical resection can be curative for epilepsy indicates that affected
regions are physiologically different from their normal counterparts.

These physiological

differences are likely downstream consequences differences in gene expression between epileptic
and non-epileptic regions. These differences may further manifest as metabolic differences and
be reliably probed by the right tool and used as crucial biomarkers for epileptogenesis or act as
surrogate markers for therapeutic efficacy. The ability to simultaneously measure numerous
spatially localized compounds associated with brain metabolism and the relative ease by which
the technique may be translated between in vitro, ex vivo, and non-invasive in vivo applications,
makes MRS a tremendously powerful tool for studying epilepsy and for identifying biomarkers
of the disorder. We hypothesized that we can indeed identify potential metabolite biomarkers
that are predictive of epilepsy and epileptogenesis using 1H MRS techniques and have
formulated our aims and approach accordingly. The section below (Chapter 1, Section 1.4)
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provides further details on the aims and scopes of this project.

Additional information on the

theory of MRS, what it measures, and how it has been applied to epilepsy thus far are provided
in Chapter 2.
1.4 Project scope and aims
There are 2 central aims we hope to address in this project: 1) identification of potential
biomarkers of established epilepsy in human tissue and 2) identification of potential biomarkers
for the development of epilepsy in an appropriate animal model of epileptogenesis and determine
whether these biomarkers of epileptogenesis share commonalities with those of established
epilepsy as identified in aim 1.
To address our first aim of identifying biomarkers in established epilepsy, we applied a
high resolution version of 1H MRS to surgically resected epileptic and non-epileptic (based on
their relative levels of IED activity) tissue samples ex vivo. These tissue samples are acquired
from patients with intractable epilepsy undergoing surgical resection of their epileptic focus as
part of their clinical treatment plan. Using an unbiased statistical classification approach, we
demonstrate the ability of 1H MRS ex vivo to identify a unique metabolite profile capable of
distinguishing between epileptic and non-epileptic tissue samples. We also integrated these
metabolite findings with findings obtained from parallel transcriptional microarrays and
histology studies to help us better appreciate the possible molecular and cellular features
contributing to these metabolite differences. The details of this study are given in Chapter 3.
Studying tissue samples from intractable epilepsy patients allows us to characterize the
metabolite profiles of long established epilepsy, but does not necessarily give us information
about metabolite changes associated with the development of epilepsy (i.e. epileptogenesis).
Studying the latter requires a longitudinal study design, which is most easily implemented in a
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suitable animal model of epileptogenesis since we do not have the ability to predict or monitor
this process in human patients. Hence, to accomplish our second aim of identifying biomarkers
of epileptogenesis, we turned to a rat model of epileptogenesis with persistent and spontaneous
IEDs and similar molecular changes in MAPK-CREB expression, achieved by injecting tetanus
toxin directly into the animal’s somatosensory cortex. After treatment with tetanus toxin, we
followed these animals longitudinally over the course of five weeks by performing EEG
recordings and

1

H MRS scans at periodic intervals to study the interaction between

electrophysiology and metabolite levels over time. These animal studies will further help to
determine whether or not IEDs could sufficiently account for the metabolite differences observed
in our ex vivo human study. Detailed descriptions of this study are provided in Chapter 4.
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CHAPTER 2: BRIEF INTRODUCTION TO MRS AND ITS APPLICATIONS IN
EPILEPSY
2.1 What is MRS and what does it measure?
MRS, also commonly known as nuclear magnetic resonance (NMR) spectroscopy, is one
of the oldest magnetic resonance based analytical techniques and the subject of two Nobel Prizes
in Physics. The first was awarded to Isidor Isaac Rabi in 1944 for discovering the NMR
phenomenon (Nobel Media AB, 2014a) and the second was shared between Felix Bloch and
Edward Mills Purcell in 1952 for applying NMR in a way that enabled analysis of ordinary
liquids and solids (Nobel Media AB, 2014b). While a full treatise on the theory of MRS and its
applications is beyond the scope of this work, a basic summary of relevant concepts is provided
and a more thorough treatment of the subject may be found elsewhere (De Certaines, Bovée, &
Podo, 1992; De Graaf, 2007; Keeler, 2005).
NMR is a phenomenon where a population of atomic nuclei possessing both intrinsic
magnetic moment and angular moment (i.e. non-zero spin), will align themselves along an
external magnetic field (B0) with a net magnetization M0 and precess at a characteristic
resonance frequency, known as the Larmor frequency (Figure 2.1A). This precession frequency
(ω, in rad sec-1, or ν, in sec-1 or Hz) is predicted by the Larmor equation (Equations 1.1 and 1.2)
and is proportional to the strength of the external magnetic field (in Teslas or T) and intrinsic
properties of the nucleus given by the gyromagnetic ratio (γ, in rad sec-1 T-1). These nuclei can
be induced to change orientation when under the influence of an applied magnetic field (B1) that
is usually perpendicular to B0 (Figure 2.1B) and is generated by an excitatory radio frequency
(RF) pulse delivered at the same resonant frequency. As the nuclei relax back to equilibrium, the
transverse component of their net magnetization will produce a decaying RF signal with their
precession frequency as the carrier frequency (Figure 2.1C-D). This decaying RF signal, called
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the free induction decay (FID), is detected by the receiver coil and contains useful information
about the nuclei that generated it.
ω!=!γB0

(Equation 1.1)

ω
γ
= B0
2π 2π

(Equation 1.2)

ν=

A

B

z
B0

C

z

D

z
B0

ω
M0

M0

M0
y

y

time
y

B1
x

x

x

t=0

Figure 2.1 Creation of a transverse magnetization. A) Net magnetization (M0) is created in the
presence of an external magnetic field B0. B) Application of a perpendicular magnetic field (B1)
causes M0 to precess about B1. C) Turning off B1 after M0 has been flipped 90° will cause M0 to
precess about B0 once again, but in the transverse plane. D) This transverse magnetization is
detected in a receiver coil as it relaxes back to equilibrium, generating the FID signal.
The Fourier transform can be applied to this time domain signal to obtain the frequency
components that make up the signal in the form of peaks along a frequency axis, in what is
referred to as a spectrum. Ideally, when there is no delay in signal acquisition from the moment
the FID is formed, the number of nuclei contributing to the peak is proportional to the integrated
area under the peak. A larger area under the peak at a particular frequency indicates more nuclei
contributing to the signal at that frequency. The shape of the peak is strongly influenced by the
FID decay rate; lower decay rates result in taller but narrower peaks, faster decay rates result in
shorter but broader peaks, whilst area under the peak remains the same.
Theoretically any nucleus with non-zero spin, typically isotopes with odd atomic
numbers, may be studied using MRS. However, only a relatively short list of nuclei can be
studied practically due to restrictions on time, equipment, and abundance. Some of the most
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commonly studied nuclei include: 1H,

31

P,

13

C,

23

Na, and

19

F. For biological applications, 1H

MRS (i.e. applying the RF pulse at the resonance of the 1H isotope) is generally the most
common due to its relatively high sensitivity, owing to its high abundance. It also has the ability
to simultaneously probe for multiple metabolites that affect various aspects of cell function from
membrane components to neurotransmitters. In general, 1H MRS is able to reliably detect
metabolites with concentrations of 0.5 to 1 mmol/kgwet weight or greater (Govindaraju, Young, &
Maudsley, 2000). The work presented here also uses 1H MRS to identify potential biomarkers of
epilepsy.
Within a particular compound, MRS is able to resolve and characterize specific chemical
moieties involving the nucleus of interest along a chemical shift frequency axis. Each peak
along this chemical shift axis reflects the unique resonance frequency (ν) of a particular chemical
moiety contain the nucleus of interest. For practical purposes, these frequencies are generally
represented as a chemical shift (δppm) relative to a reference frequency (νref) in parts per million
(ppm), which makes it independent of magnetic field strength (Equation 1.3). The additional
scaling factor of 106 is included to improve legibility, since the shift value is generally very small.
δppm =

ν − νref
νref

& × &106

(Equation 1.3)

Chemical shifts result from differences in the local magnetic environment experienced by
the nuclei of interest. The presence of an electron cloud near a nucleus produces a shielding
effect that decreases the strength of the external magnetic field experienced by the nucleus. As a
result, the nucleus will precess at a lower resonant frequency than a similar nucleus with less
shielding.

To illustrate, long triglyceride fatty acid chains with its dense arrangement of

hydrogen atoms along a carbon backbone will have a larger electron cloud and consequently
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experience stronger shielding than the hydrogen atoms in water, which experiences significantly
less shielding in the presence of the electronegative oxygen atom. This difference in shielding
produces a 3.5 ppm chemical shift between the water and fat peaks on the chemical shift axis.
Most of the metabolites examined in 1H MRS fall between the water and fat peaks. Typical
metabolites peaks found in 1H MRS in vivo are described in Table 2.1.
Metabolite Chemical Shift (ppm)

Key Function

Cr+PCr

3.03

Energy metabolism; ATP generation via CK reaction

Gln

2.45

Component of glutamate-glutamine cycle; converted from glutamate in
astrocytes

Glu

2.35

Excitatory neurotransmitter; component of glutamate-glutamine cycle

GPC+PCh

3.20

Intermediates of membrane phospholipid breakdown (GPC) and
synthesis (PCh) pathways

Lac

1.31

Indicator of hypoxia; insufficiency of oxidative phosphorylation

m-Ins

3.52, 3.62

NAA

2.01

Part of IP3 intracellular second messenger system
Marker of neuronal integrity

Table 2.1 List of common metabolites seen in vivo, their chemical shift positions, and their
known key functions. In general, NAA, Cr+PCr, and GPC+PCh are the three most visible
metabolite peaks on 1H MRS. Lac is generally below threshold of detection under normal
physiologic conditions. Glutamate and glutamine peaks show significant overlap at 1.5 T but
may be resolved reliably at 3 T or higher. Creatine plus phosphocreatine (Cr + PCr) , glutamine
(Gln), glutamate (Glu), glycerophosphorylcholine plus phosphorylcholine (GPC+PCh), lactate
(Lac), myo-Inositol (m-Ins), N-acetylaspartate (NAA).
To enable spatial localization in MR studies, magnetic field gradients can be added
linearly to the main magnetic field as a function of position, such that different locations will
experience a slightly different magnetic field strength. Referring back to the Larmor equation
(Equation 1.1), a natural consequence of this spatially dependent variation in magnetic field
strength is that the nuclei in each of those locations will also precess at a different resonant
frequency, depending on where they are located in space. Frequency selective RF pulses can
then be applied to study only those nuclei in the region of interest (ROI).
Single voxel spectroscopy (SVS) and MR spectroscopic imaging (MRSI) are the two
most common techniques used for spatial localization in MRS studies.

SVS uses three
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orthogonal slice selective RF pulses to isolate a rectangular or cubic ROI, located at the
intersection of those three orthogonal slices. This region of interest may be moved about and
adjusted to an adequately small size to ensure that it is not contaminated with signals from
adjacent tissue. However, SVS can only acquire from a single location at a time and generally
require multiple averaging scans (typically 64 to 256) to produce a spectrum of reasonably
quality. This makes the scanning of a large number of voxels prohibitively time consuming. To
collect spectra from a larger area, MRSI, which uses a localization scheme different from SVS,
can be more efficient approach, as it can makes use of every scan done over the entire area to
improve the signal to noise ratio of every voxel in a large array of voxels. The larger ROI
associated with MRSI will, however, place a much greater demand on the shim systems to
maintain magnetic field homogeneity over the entire area (Hetherington, Kim, Pan, & Spencer,
2004). Poor magnetic field homogeneity will create large variances in precession frequency
within the ROI due to the variations in the magnetic field strength. This results in broader peaks
in the frequency domain and impairs the ability of MRS to resolve and quantify the detected
compounds due to increased overlap of peaks that would have been adequately separated from
each other otherwise.
While in vivo MRS studies are most ideal for studying the metabolite profile in living
organisms, high resolution MRS studies performed on biological samples ex vivo can provide
provide a wealth of metabolite information with exquisitely high sensitivity not typically
achievable in vivo. One particular ex vivo 1H MRS approach, known as high resolution magic
angle spinning 1H MRS (HR-MAS 1H MRS), is unique its ability to analyze frozen intact tissue
without the need for histologically disruptive chemical extractions.

It does so by rapidly

spinning the sample at the so-called magic angle of 54.7° relative to main static magnetic field in
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order to minimize the spectral-broadening effects of dipole-dipole interactions in solid state
samples (Andrew, Bradbury, & Eades; Beckonert et al., 2010). For the study of intact tissue
samples, this technique is superior to many of the common chemical extraction procedures,
where the choice of solvent will impact the types of metabolite available for analysis (e.g.
hydrophilic versus hydrophobic) and any available information on tissue compartmentalization
and localization would also be completely lost (Beckonert et al., 2010; Cheng et al., 1996;
Srivastava et al., 2008).
MRS is an inherently non-invasive technique that relies primarily on strong magnetic
fields and RF pulses to generate signals of interest that contain valuable information about the
concentrations, characteristics, and environments of the compounds contributing to the signals.
The ability to change the size and location of ROIs also allows MRS to be very selective about
which sites to study while still being flexible enough to study much larger areas (e.g. the entire
brain) as needed. When used as a complement to other experimental procedures, MRS can also
characterize in vitro and ex vivo samples, providing results that may be translated to their in vivo
counterparts with relative ease. These are all very important features for any potential biomarker
tool, but especially so for epilepsy, as we would greatly benefit from being able to perform
multiple longitudinal measurements to track biochemical changes in the brain, particularly in
regions that are most relevant for seizure generation. We can further complement these findings
with additional experimentally derived findings obtained ex vivo or in vitro. For these reasons,
MRS can be an extremely powerful tool for the study of epilepsy biomarkers.
2.2 MRS in epilepsy
While 1H MRS is primarily used as an adjunct diagnostic tool for epilepsy in the clinical
setting, it can still give important lateralization or localization information, especially in more
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difficult cases with negative or ambiguous MRI and EEG findings. In a research capacity,
epilepsy has been studied since the mid-1980s using

31

P MRS, a method that preferentially

probes metabolites associated with tissue energetics such as high-energy phosphates groups of
ATP, phosphocreatine (PCr) and low energy inorganic phosphate (Pi). In general, however,
there have been more 1H MRS epilepsy studies than

31

P due to its relatively high sensitivity,

which leads to greater spatial resolution. Furthermore, from a hardware perspective,
studies require dual-tuned coils to probe both 1H and

31

31

P MRS

P nuclei at their own unique resonant

frequencies, which is frequently unavailable on clinical MR systems.
The earliest

31

P MRS studies characterized animal models during status epilepticus and

noted decreases in both PCr and cerebral pH (Petroff, Prichard, Behar, Alger, & Shulman, 1984)
as well an elevation in Pi (Young et al., 1989). Concordance between temporal lobe epilepsy
lateralization using PCr/Pi and ATP/Pi ratios and final clinical lateralization has been reported to
be 70-73%, which was superior to lateralization by MRI or scalp EEG alone (Chu et al., 1998).
Later

31

P MRS studies of temporal lobe epilepsy patients provided evidence of bioenergetic

impairments with consistent decreases in the PCr/Pi ratio (Kuzniecky, Elgavish, Hetherington,
Evanochko, & Pohost, 1992) as well as ATP/Pi (Chu et al., 1998) and PCr/ATP (Hetherington et
al., 2004). The decreases in PCr/Pi and PCr/ATP may be mitigated or reversed by initiation of
the ketogenic diet in some intractable epilepsy cases (Pan, Bebin, Chu, & Hetherington, 1999).
Over the last several decades, most 1H MRS studies of epilepsy, particularly those
involving temporal lobe epilepsies, have consistently reported decreases in N-acetylaspartate
(NAA), expressed either independently or as a ratio with creatine plus phosphocreatine
(Cr+PCr), glycerophosphorylcholine plus phosphorylcholine (GPC+PCh), or Cr+PCr plus
GPC+PCh (Cr+PCr+GPC+PCh) (Bernasconi, Tasch, Cendes, Li, & Arnold, 2002; Breiter et al.,
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1994; Cendes, Caramanos, Andermann, Dubeau, & Arnold, 1997b; Connelly, 1997; Matthews,
Andermann, & Arnold, 1990). NAA is considered to be a marker of neuronal healthy and
participates in a number of biochemical processes, including lipid synthesis and mitochondrial
energy production (Moffett, Ross, Arun, Madhavarao, & Namboodiri, 2007). The reduction of
NAA does not necessarily correlate to neuronal loss in epilepsy (Kuzniecky et al., 2001; Petroff,
Errante, Rothman, Kim, & Spencer, 2002) and may be reversed in many cases after successful
resective surgery (Cendes, Andermann, Dubeau, Matthews, & Arnold, 1997a; Hugg et al., 1996;
Serles et al., 2001). Despite the fewer number of studies on non-lesional and non-temporal lobe
epilepsies, similar decreases in NAA and its ratios to Cr+PCr, GPC+PCh, and
Cr+PCr+GPC+PCh, have also been reported (Connelly et al., 1998; Garcia et al., 1995; Stanley,
Cendes, Dubeau, Andermann, & Arnold, 1998).
In addition to NAA, differences in glutamate, lactate, and γ-aminobutyric acid (GABA)
levels have also been reported.

Several lines of evidence point to elevated extracellular

glutamate levels compared to controls, particularly in temporal lobe epilepsies with negative
MRI findings. Glutamate is thought to play a role in promoting hyperexcitability, leading to
seizure development (Cavus et al., 2005; Pan et al., 2008; Simister et al., 2002). Patients actively
experiencing seizures or shortly after a seizure episode have also been reported to have elevated
lactate levels at or near the site of the seizure focus (Cendes, Stanley, Dubeau, Andermann, &
Arnold, 1997c). However, interictally, lactate is generally undetectable (Breiter et al., 1994) in
otherwise normal appearing tissue using standard 1H MRS approaches. Works by Petroff and
colleagues suggest that poor seizure control may be associated with lower levels of GABA in the
brain (Petroff, Rothman, Behar, & Mattson, 1996b) and treatment with certain ASDs such as
vigabatrin, gabapentin, and topiramate may increase GABA levels and consequently increase
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seizure threshold (Petroff, Hyder, Mattson, & Rothman, 1999; Petroff, Rothman, Behar, Collins,
& Mattson, 1996; Petroff, Rothman, Behar, Lamoureux, & Mattson, 1996; Petroff, Rothman,
Behar, & Mattson, 1996a).
2.3 Challenges of studying epilepsy using 1H MRS
Despite decades of available literature on 1H MRS studies of epilepsy, vast majority of
these studies focused specifically on temporal lobe epilepsies. While the study of temporal lobe
epilepsies is no doubt important, this skew also highlights the multitude of challenges associated
with using MRS for studying epilepsy and points to where progress is urgently needed.
Furthermore, the integration of multiple experimental modalities in addition to 1H MRS is
needed to better characterize the biochemical changes underlying the observed metabolite
differences in order better understand and validate the ability of 1H MRS to identify key
biomarkers in epileptogenesis and to serve as a surrogate marker of therapeutic efficacy.
First, most existing 1H MRS methodologies do not have the coverage necessary to study
the entire brain with high spatial resolution. Traditional single voxel techniques require the
regions of interest to be defined a priori, which is frequently the hippocampus in the case of
temporal lobe epilepsies. However, such prior knowledge is generally unavailable for nontemporal lobe cases, particularly in the more difficult cases with negative anatomic MRI
findings. While spectroscopic imaging studies have made some headway in characterizing the
metabolomic profile of epileptic versus non-epileptic brain regions by providing increased
coverage with relatively high spatial resolution generally along a pre-defined two-dimensional
plane, this plane of interest needs to be defined a priori, and as a result these studies also tend to
focus on the temporal lobe structures (Hetherington et al., 2007; Pan et al., 2012). Only recently,
with continued development of the echo-planar spectroscopic imaging (EPSI) technique (Posse,
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DeCarli, & Le Bihan, 1994) by Maudsley and colleagues, has whole brain coverage become a
possibility (Maudsley et al., 2006; Maudsley et al., 2009a; Maudsley, Domenig, & Sheriff,
2009b). The application of this technique to epilepsy has been promising for non-temporal lobe
epilepsies and its findings have been consistent with those in existing literature (Maudsley,
Domenig, Ramsay, & Bowen, 2010; Mueller et al., 2010).
Second, existing MRS studies of epilepsy generally do not have the spatial resolution
needed to selectively study a particular tissue type but will instead capture a mixture of gray
matter, white matter, and cerebrospinal fluid (CSF) in what is called a partial volume effect.
This distinction is important because gray and white matter have differing concentrations of
metabolites (Hetherington et al., 1994; Hetherington et al., 1996; Kreis, Ernst, & Ross, 1993).
Therefore, varying ratios of gray matter, white matter, and CSF can dramatically impact the
interpretation of the findings in a typical MRS study. Although the metabolite values may be
statistically corrected to improve sensitivity (Chu et al., 2000), many studies do not perform such
corrections or may opt to circumvent the issue by judicious placement of the ROI over a
particular structure of interest (e.g. hippocampus). Given the layer-specific distribution of gene
expression differences between epileptic and non-epileptic neocortex observed by our laboratory,
this issue of gray and white matter composition would appear to be especially important to
consider in an MRS study of neocortical epilepsy.
Finally, very few studies have examined the relationship between 1H MRS metabolites
and electrophysiology parameters such as IEDs or seizure frequency (Hammen et al., 2007; Park
et al., 2002; Serles, Li, Caramanos, Arnold, & Gotman, 1999), and even fewer studies have
attempted to further examine those changes in the context of genetic or histologic changes
between epileptic and non-epileptic regions (Peeling & Sutherland, 1993; Petroff, Pleban, &
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Spencer, 1995) and none of them were done in recent years. The past several years have seen an
increased ubiquity of high field strength systems with more advanced hardware capabilities
resulting in much improved sensitivity. With this increase in the power of 1H MRS to detect
metabolite differences, interpretation and validation of these differences becomes increasingly
important in the process of identifying reliable and relevant biomarkers for epilepsy that may be
translated for clinical use.

This degree of validation and characterization can only be

accomplished through the combination of multiple experimental modalities and approaches.
This project seeks to address some of these issues by combining 1H MRS measurements
with other transcriptional, cellular, and electrophysiological parameters collected in parallel with
our well localized ex vivo tissue from the superficial layers of the epileptic human neocortex.
Our end goal is to identify relevant 1H MRS metabolite biomarkers that can also inform us about
the underlying molecular changes taking place in these patients. Our longitudinal study using a
rat model of epileptogenesis in vivo attempts to investigate the complex relationship between
electrophysiological changes and metabolite changes in the rat neocortex overtime. The results
from this in vivo animal study can also serve as a validation of our findings from the ex vivo
human tissue study.
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CHAPTER 3: A UNIQUE METABOLITE PROFILE PREDICTIVE OF EPILEPTIC
NEOCORTEX IN HUMANS EX VIVO
3.1 Summary
Identifying biomarkers that reliably detect epileptic brain regions is crucial for accurate
diagnosis and therapy development. At present, only surgically invasive, direct brain recordings
are capable of detecting these regions with precision. We performed an integrated metabolomicgenomic-histological analysis of electrically mapped human cortical tissue samples from
epilepsy surgery patients using high resolution magic angle spinning (HR-MAS) 1H MRS and
cDNA microarrays. We found a highly consistent and predictive metabolite logistic regression
model with reduced lactate and increased creatine plus phosphocreatine (Cr+PCr) and choline
(Cho), suggesting a chronically altered metabolic state in epileptic brain regions. Linking gene
expression, cellular, and histological differences to these key metabolites using a hierarchical
clustering approach revealed altered metabolic vascular coupling. Consistently, this pattern
correlated strongly to neovascularization associated with recently discovered, millimeter-sized
histological microlesions. These results provide evidence for spatially segregated metabolic
derangements indicative of underlying vascular and synaptic aberrations in human epileptic brain
regions that could be used to develop non-invasive clinical biomarkers of epilepsy.
3.2 Introduction
As mentioned in Chapter 1, epileptic regions of the brain produce abnormal synchronous
discharges across large populations of neurons. These discharges can remain isolated, as in the
case of IEDs, or they can propagate and affect large regions of the brain, resulting in seizures.
While the exact relationship between interictal spiking and seizures is not understood (Gotman,
1991), their localization is highly concordant and the removal of both regions is associated with
improved surgical outcome (Asano et al., 2003; Bautista et al., 1999; Kanazawa et al., 1996; Lee
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et al., 2014). Animal studies have shown that interictal spikes may precede and hence be a
biomarker of seizure development (White et al., 2010). Here, we are specifically interested in
identifying metabolite biomarkers that can classify high versus low spiking tissue samples, with
the inference that high spiking activity more readily reflects epileptic tissue while low to no
spiking tissue more readily reflects normal tissue.
As part of our systems biology of epilepsy program (SBEP) (Loeb, 2011), we collected
electrically-mapped regions of human neocortex from patients undergoing long-term invasive
monitoring with ECoG to localize precisely regions that produce seizures and interictal spiking
(Loeb, 2011) (Figure 3.1). SBEP was designed to integrate quantitative clinical, neurochemical,
electrical, and genomic signatures of different brain regions with and without significant
epileptic activities (Beaumont et al., 2012; Dachet et al., 2015; Lipovich et al., 2012; Rakhade et
al., 2005). By knowing the in vivo electrical behavior of each resected piece of tissue, we have a
unique ability to compare highly epileptic brain regions to nearby electrically quiet regions of
each patient serving as internal controls. Studies from this program have implicated layer-2/3specific activation of MAPK and CREB signaling and the presence of deeper “microlesions” that
show a dramatic reduction in axodendritic connectivity in brain regions with high levels of
epileptic activity (Dachet et al., 2015).
MRS is a technique for characterizing compounds associated with tissue metabolism with
high translational potential since it can be applied to both intact tissue samples ex vivo as well as
to animal models and human patients in vivo. As reviewed in Chapter 2, previous 1H MRS
studies of epilepsy have demonstrated perturbations in the neurochemistry of epilepsy patients
and have assisted in efforts to lateralize or localize the epileptic focus, particularly in temporal
lobe epilepsies; however, a highly sensitive and specific set of non-invasive biomarkers have yet
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to emerge in part due to uncertainties in localization, poor spatial distinction of epileptic and
non-epileptic brain regions, and studies being done using relatively low field strength MR
systems (e.g. 1.5T systems).
Here, we addressed these challenges by using human tissues precisely localized from
ECoG brain recordings in vivo and analyzed the samples by using an ultra-high field
spectrometer at 11.7 T using HR-MAS 1H MRS, which allows for metabolite profiling of intact
brain tissue with superior spectral resolution (Andrew et al., 1959; Cheng et al., 1996; Cheng et
al., 1997). We asked whether focal regions of human neocortex have a unique metabolomic
signature that may be adapted for use as non-invasive biomarkers of epileptic activity. More
specifically, we performed HR-MAS 1H MRS on neocortical tissue samples from 9 patients
undergoing surgical treatment for their intractable epilepsy. Their clinical ECoG data were used
to quantify the interictal spiking rates in various regions of their brain in order to identify which
tissue sample can be classified as high spiking and which sample can be classified as low
spiking. Using the measured metabolites, we were able to construct a metabolite profile that is
able to predict whether or not a particular piece of tissue sample was high or low spiking with
great accuracy. We also performed additional genome wide expression studies using Agilent
microarrays and histology on the same tissue samples to characterize transcriptional, cellular,
and histological features associated with their metabolite profile (Figure 3.1).
Given the robust gene expression differences between high and low interictal spiking
activity in MAPK/CREB activation and the downstream consequences they would presumably
have on protein and small molecule expression, we expect to be able to detect differences in
downstream 1H MRS metabolite levels between high and low spiking tissues.

A relative

decrease in NAA levels within high spiking regions is expected, since that is the observed
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metabolite feature of epilepsy most consistently reported in literature.

Figure 3.1 Human brain tissues were removed as part of planned surgery for refractory epilepsy.
Regions of high and low spiking were identified based on long-term subdural ECoG. Each
section of tissue was precisely mapped to the overlying subdural electrode and then split into two
halves. One half as used for histology while cortical gray matter is isolated from the other half.
The cortical gray matter is then further divided into two portions, half of which is used to
generate RNA for microarray analysis while the other half is used for HR-MAS 1H MRS.
3.3 Methods
3.3.1 Isolation of human tissue and electrophysiology
Brain tissue samples from our 9 human subjects with refractory epilepsy were obtained
with informed consent as part of a research protocol approved by the Wayne State University
Institutional review Board and their participation in the study had no influence on their clinical
care or treatment plan. Their age, gender, and other relevant clinical features are given in Table
3.1. All 9 subjects underwent two-stage surgery with long-term subdural ECoG, where Stage 1
consisted of initial electrode placement for long-term recording and observation, followed by
Stage 2, where the seizure generating areas identified in Stage 1 were resected. Briefly, interictal
spiking activity on ECoG were determined by averaging spike counts from 3 independent 10 min
segments of ECoG recording, which were continuously recorded for at least 3 days prior to
resection. Electrode placements were mapped precisely to their corresponding locations on the
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neocortex using a combination of intraoperative electrode placement photos, as well as pre- and
post-placement head CT, MRI, and X-rays. A tissue sample block at each electrode location was
removed and divided into two halves. One half fixed in 4% paraformaldehyde for use in
histological studies while the other half was stored frozen at minus 80°C until it can be used for
further analysis (Figure 3.1).
Patient ILAE
Classification
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7.6
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6.9

10.6

17.5

9
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6

11

F Frontal

I
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2

66

4.8

4.1

8.9

Normal

16.8

Table 3.1 Profile of patients with neocortical epilepsy and the corresponding tissue samples that
were used for this study. Spike frequency reflects epileptiform spike rates for both high and low
spiking regions in the patient’s brain, recorded in vivo using ECoG as part of their clinical
treatment plan. Microarray characteristics show percent of genes that are at least 1.4 fold
increased or decreased (after FDR correction to 1%) in expression in high spiking relative to low
spiking samples. Documented tissue pathologies (“Other tissue diagnoses”) were made from
separate clinical tissue samples and were not present in the tissues used for this study, which
were normal appearing on histology. Abbreviations: acute inflammation (AI), blurring of greywhite junction (BGW), bifrontal subcortical heterotopias (BSH), cortical dysplasia (CD),
probable cortical dysplasia (CD?); diffuse gliosis (DG), epileptic spasms (ES), heterotopia (H),
mild cortical dysplasia (MCD), mild gliosis (MG), data not available (NA), normal laminar
pattern (NLP), polymicrogyria (P), partial complex (PC), periventricular mild increase in FLAIR
(PE), porencephalic cyst (PO), secondary generalized: evolution from focal to bilateral,
convulsive seizure (SG), superficial heterotopia (SupH), thickened cortex (TC), increased white
matter signal (W), white matter gliosis (WG).
Because of the great variance between patients in absolute spike frequency between
regions considered for high and low spiking, we dichotomized spike frequency into “high” and
“low” spiking categories in order to reduce strong leverage effects.

For each patient, the

subdural electrode demonstrating the highest spiking frequency was classified as “high spiking”
and the electrode with the lowest or no spiking is classified was “low spiking.” In this manner,

24
high and low spiking electrodes for each patient were identified and analyzed using both
microarray and HR-MAS 1H MRS at 11.7T. For the purposes of this study, low spiking
electrodes were considered internal controls for each patient, effectively controlling for withinsubject tissue variability (Loeb, 2010). All tissue regions selected for this study were free of
apparent pathological changes and surgical hemorrhage based on gross examination and
histology. Histological tissue studies were done as described in our previous study (Dachet et
al., 2015).
3.3.2 Microarray analysis and detection of differentially expressed genes
For microarray studies, total RNA was isolated from pooled alternating strips of fullthickness (layers I-VI) neocortical gray matter, helpful in averaging out small local differences.
A quadruplicate, flip-dye experimental design, as described (Beaumont et al., 2012; Rakhade et
al., 2005), was used for each pair of high and low spiking samples within every patient. Briefly,
labeled antisense RNAs were spin column purified and hybridized to human, genome-wide 60mer oligonucleotide arrays (Catalog #G411A, Agilent), in a two-color dye-swap fashion.
Differentially expressed genes were identified with a two-step hierarchical linear mixed model,
correcting for array, dye, patient, array-die interactions and within-patient effects. Genes that
had more than a 1.4-fold change between high and low spiking samples with a false discovery
rate of < 0.01 were considered to be differentially expressed.

We identified 990 such

differentially expressed genes from our samples obtained from 9 subjects.
3.3.3 High resolution Magic Angle Spinning 1H MRS
HR-MAS 1H MRS spectra were acquired from 2 mm punches obtained from the apical
neocortical gray matter (layers I-III), for each pair of high and low spiking samples within every
patient in triplicate, at minimum, while frozen on solid CO2. Tissue samples that were larger in
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size may have more than 3 replicates. The median number replicates for low spiking tissue was
4 with a range from 3 to 8 and the median number of replicates for high spiking tissue was 6 with
a range from 3 to 9. The frozen punches analyzed using HR-MAS 1H MRS on a 500 MHz
(11.7T) Bruker Avance DRX-500 spectrometer equipped with a g-HR MAS 500 WB BL4 P-HD
probe (Bruker BioSpin Corporation, Billerica, MA) as described by Ghoddoussi and colleagues
(Ghoddoussi et al., 2010). The samples were placed directly into a Bruker zirconium rotor
containing 5µL phosphate buffer (pH = 7.4), D2O, trimethylsilyl-proprionate (TSP) as the
internal chemical shift reference (0.00 ppm), and formate for phase correction (8.44 ppm). The
sample was maintained at 4°C and spun at 4.2 ± 0.002 kHz while positioned at 54.7° relative to
the static magnetic field, B0. Semi-automated and manual first and second order shimming was
used to reduce field inhomogeneities. A rotor-synchronized 1-D Carr-Purcell-Meiboom-Gill
(CPMG) with [90°-(τ-180°-τ)n] pulse sequence was used to acquire tissue spectra (Cheng et al.,
1996). To take advantage of CMPG ability to filter out signals from molecules with short T2
relaxation values, such as large signals from fat (Mountford, MacKinnon, Delikatny, & Russell,
1992), twelve echo pulses were applied (n = 12) with an inter-pulse delay (τ) of 150 µs for TE =
3.6 ms (echo time) and TR = 6.21 s (repetition time). All spectra were acquired at a spectral
bandwidth of 7 kHz (14 ppm) with 128 averages for a total acquisition time of approximately 13
min per sample. A representative high quality sample spectrum is given in Figure 3.2.
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Figure 3.2 Representative high quality HR-MAS 1H MRS spectrum of human brain performed
on partial thickness neocortical sample (layers I-III). LCModel fitted spectrum (red line) shows
excellent correspondence with averaged raw signal (thin black line). Abbreviations: free choline
(Cho), creatine plus phosphocreatine (Cr+PCr), γ-aminobutyric acid (GABA), glutamine (Gln),
glutamate (Glu), glycerophosphorylcholine (GPC), myo-inositol (m-Ins), lactate (Lac),
macromolecules at 1.4 ppm (MM140), N-acetylaspartate (NAA), N-acetylaspartylglutamic acid
(NAAG), phosphorylcholine (PCh), phosphorylethanol-amine (PE), taurine (Tau).
3.3.4 1H MRS quantitation
The raw 1H MRS spectra were analyzed using LCModel (Provencher, 1993) with a
custom experimentally derived basis-set containing 27 individual neurochemical metabolite
model spectra combined with simulated lipid and macromolecule signals. The experimentally
derived basis-set was obtained under identical experimental conditions as the tissue analysis. A
complete list of all the metabolites included for fitting is provided in Appendix A.

The

concentrations of metabolites located between 1.0 to 4.5 ppm, a range containing the major
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resonances from all the metabolites of interest, were estimated using LCModel.

These

concentrations were ultimately expressed as a normalized mole percent of total metabolites,
allowing measurements to be relatively insensitive to changes in extracellular volume (Klunk,
Xu, Panchalingam, McClure, & Pettegrew, 1994). LCModel’s estimated confidence of the fitted
metabolite spectra (i.e. how well it matches the original data) is estimated using Cramér-Rao
Lower Bounds (CRLB). For this study, only metabolites with average CRLB values less than or
equal to 10% were used for analysis.
3.3.5 Tissue discrimination and clustering
In order to get a general sense of whether or not there are detectable differences in
metabolites between high and low spiking regions, a t-test was initially performed on all 14
metabolites of interest to determine if significant differences exist between the metabolite in high
and low spiking tissues. More refined classification and discrimination of high and low spiking
samples using the metabolite profiles of all the samples were performed using generalized
estimating equation (GEE) logistic regression model with an exchangeable covariance matrix
implemented in R with geepack (Højsgaard, Halekoh, & Yan, 2005; Team, 2014) to help account
for within-subject variability, since the samples were measured in multiplicates.

Receiver

Operating Characteristic (ROC) curves, as a measure of model performance, were calculated
using pROC package, together with a bootstrap estimated 95% confidence interval of the model
sensitivity (Robin et al., 2011).
Because several metabolites were highly correlated (r > 0.8) with each other, principal
components analysis (PCA) was initially used to address the underlying issue of
multicollinearity. Since the goal of our PCA analysis was to minimize multicollinearity, we
chose to include the maximum number of components possible (i.e. 14 components) for our full
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model GEE logistic regression, in order to make predictions on whether a particular tissue
sample is high or low spiking. The appropriateness of using the varimax orthogonal rotation
method of PCA is validated by both an adequate Kaiser-Meyer-Olkin measure of sampling
accuracy (MSA = 0.84) as well as significant Bartlett’s test of sphericity, χ2(91) = 1109, p <
.001, indicating that the data is appropriate for PCA analysis (Dziuban & Shirkey, 1974). The
resultant factor scores were used as predictors in our logistic regression model. This resultant
logistic regression model used a given sample’s measured metabolite profile to determine a
predicted probability ( p̂ ) that the sample was a high spiking sample.
The full 14 component model performed extremely well in discriminating high versus
low spiking tissue with an ROC area under the curve (AUC) of 0.90, 95% CI [0.83, 0.96] (Figure
3.3). For comparison, the AUC for the diagonal line on the ROC is 0.50, and represents the
performance of chance classification (i.e. random guessing). A maximum accuracy of 83%
along with 85% sensitivity and 81% specificity was achieved using cutoff threshold of 0.57,
where all p̂ ≥ 0.57 would be considered “high spiking” while those below the cutoff would be
considered “low spiking.” Gender was not included as a covariate in the model due to the highly
uneven distribution between female (n = 7) and male (n = 2) participants. Effects of both region
(based on electrode placement) and subject age were tested and determined to have insignificant
effects on the model overall (χ2 (1) = 0.213), and hence were removed from all analyses to
reduce over fitting.

The component playing a significant role (Wald p-values < 0.10) in

discriminating high from low spiking samples were identified and from them, we then selected
the key metabolite from each component demonstrating the highest loading factor from
metabolites that showed loading factors of at least 0.80.
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Figure 3.3 Logistic regression performed using the maximum 14 components obtained from
principal components analysis demonstrates high sensitivity and specificity in discriminating
high spiking tissue samples from low spiking tissue samples. A) Distribution of high and low
spiking tissue samples (red and blue shading, respectively) and their predicted probabilities of
being high spiking are illustrated in the histogram. B) Overall model performance is
characterized by a receiver operating characteristic (ROC) area under the curve (AUC) of 0.90,
indicating excellent discrimination between high and low spiking tissues. Gray regions and
horizontal error bars indicate the estimated 95% confidence intervals of sensitivity and
specificity using non-parametric bootstrapping of 1000 samples
To better understand the mechanisms behind the differences in metabolite expression,
these metabolites of interest are used for additional correlational clustering studies in order to
observe how changes in key metabolites can correspond to changes in gene expression and cell
type distribution. Pearson correlations between the 990 differentially expressed genes (described
above) across the 18 high and low spiking samples obtained from our 9 subjects and their
corresponding mean metabolite concentrations for each sample were calculated (Dachet et al.,
2015). Linkages between two genes were created when Pearson correlations were ≥ 0.70. This
cutoff is also consistent with a false discovery rate (FDR) of < 0.07 (Benjamini & Hochberg,
1995). Clusters were further analyzed using a combination of ConsensusPathDB (Kamburov,
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Stelzl, Lehrach, & Herwig, 2013) and primary literature searches for functional and pathway
enrichment. For enriched pathways proposed by ConsensusPathDB, a cutoff threshold of FDR
adjusted p < 0.05 was used to selected potentially significant pathways associated with each
metabolite-gene clusters. Additional associations between metabolites and putative cell types are
explored using Pearson correlation based hierarchical clustering using the average linkage
method. Cluster relationships are further characterized using the actual Pearson correlations
themselves, where Pearson correlations ≥ 0.70 (FDR adjusted p < 0.05) are considered
statistically significant.
3.4 Results
Overall, the acquired 1H MRS signals were of very high quality. The mean signal to
noise ratio (SNR) was estimated to be 34.3 ± 8.41 (mean ± s.d) by LCModel. A total of 14
metabolites with mean CRLB of less than or equal to 10% were used for analysis. They were:
choline (Cho), glycerophosphorylcholine (GPC), γ-aminobutyric acid (GABA), glutamine (Gln),
glutamate (Glu), myo-inositol (m-Ins), lactate (Lac), N-acetylaspartate (NAA), N-acetylaspartyl
glutamic acid (NAAG), phosphorylcholine (PCh), phosphorylethanolamine (PE), taurine (Tau),
simulated macromolecule at resonance position 1.40 ppm (MM140) and creatine plus
phosphocreatine (Cr+PCr).
Mean values for the 14 metabolites in high spiking and low spiking tissue samples are
summarized in Table 3.2. Statistically significant (p < 0.05) differences between high and low
spiking tissues based on Student’s t-tests were found in 4 of 14 metabolites, namely Cho, PCh,
Lac, and PE. All were decreased in high spiking tissue.

31
Metabolite Low Spiking High Spiking Percent
t-Test
Mean (SE)
Mean (SE) Change (p, 2-tailed)
* Cho

0.61 (0.04)

0.50 (0.02)

-19%

.01

Cr+PCr

8.55 (0.24)

8.36 (0.21)

-2%

.56

GABA

3.13 (0.11)

3.10 (0.09)

-1%

.79

Gln

3.75 (0.25)

3.53 (0.15)

-6%

.44

Glu

7.03 (0.19)

6.81 (0.21)

-3%

.44

GPC

0.58 (0.03)

0.58 (0.03)

0%

.98

m-Ins

5.11 (0.22)

4.63 (0.15)

-9%

.07

15.06 (0.38)

12.98 (0.48)

-14%

< 0.001

MM140 28.80 (1.62)

32.17 (1.42)

12%

.12

NAA

5.40 (0.20)

5.21 (0.18)

-3%

.49

NAAG

0.99 (0.03)

1.00 (0.03)

1%

.78

*** PCh

0.93 (0.04)

0.78 (0.03)

-16%

< 0.01

* PE

2.36 (0.09)

2.11 (0.08)

-11%

.03

2.02 (0.09)

2.03 (0.08)

1%

.90

*** Lac

Tau

Table 3.2 Means and standard errors (SE) of key metabolites measured from tissue samples of
high and low spiking regions. Statistically significant differences were found between the high
and low spiking tissue samples in 4 out of 14 metabolites (in bold) based on two-sample t-tests.
All metabolites are normalized to the total fitted signals and expressed as percent total signal.
Percent signal changes in high spiking tissue samples relative to low spiking tissue are also
indicated for each metabolite. (* p < 0.05, ** p < 0.01, *** p < 0.001, uncorrected)
Further analysis of all 14 metabolites using a combination of PCA and GEE (Liang &
Zeger, 1986) based logistic regression yielded a short list of 8 potentially important metabolites.
Of these, 6 were identified to make significant contributions (Wald p < 0.05) in differentiating
high versus low spiking samples (Figure 3.4). They were: Cho, Cr+PCr, GPC, m-Ins, Lac, and
NAAG (Figure 3.4B and Table 3.3). Our logistic regression model performed well, with a ROC
AUC of 0.88, 95% CI [0.81, 0.95]. Our optimal accuracy in classifying high- versus low-spiking
samples using these metabolites was 82% with a sensitivity of 85% and specificity 79% (Figure
3.4C). In summary, this metabolomic signature presents a highly sensitive and specific new way
to differentiate epileptic brain regions from their non-epileptic counterparts and provides a
potential approach to non-invasively “visualize” epileptic brain regions clinically using 1H MRS.
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Figure 3.4 Logistic regression using 8 metabolites demonstrated high sensitivity and specificity
in discriminating high spiking tissue samples from low spiking tissue samples. A) Distribution of
high and low spiking tissue samples (red and blue shading, respectively) and their predicted
probabilities of being high spiking are illustrated in the histogram. B) Model coefficients used
for predicting high and low spiking tissue. Metabolites with significant (p < 0.05) contributions
to the model are bolded. C) Overall model performance is characterized by a receiver operating
characteristic (ROC) area under the curve (AUC) of 0.88, indicating excellent discrimination
between high and low spiking tissues. Gray regions and horizontal error bars indicate the
estimated 95% confidence intervals of sensitivity and specificity using non-parametric
bootstrapping of 1000 samples.
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OR

Lower

Upper

0.13

1.50

1.15

1.97

1.04

< 0.01

-6.83 (2.06)

1.83

1.08E-03

1.92E-05

6.06E-02

0.51

< 0.001

Cr+PCr

1.13 (0.22)

0.34

3.09

2.02

4.72

1.12

< 0.001

GPC

4.01 (1.45)

1.39

55.3

3.20

9.56E+02

1.49

< 0.01

myo-Ins

-0.37 (0.17)

0.16

0.69

0.50

0.97

0.96

.03

Lac

-0.74 (0.17)

0.17

0.48

0.34

0.67

0.93

< 0.001

NAAG

5.75 (2.22)

0.09

315

4.08

2.43E+04

1.78

< 0.01

PCh

-0.67 (0.91)

2.09

0.51CV

0.09

3.06

0.94

.46

PE

-1.02 (0.76)

0.81

0.36

0.08

1.59

0.90

.18

Estimate (SE)

SE

(Intercept)

0.41 (0.14)

***

Cho

***

**

**
*
***
**

95% CI for Odds Ratio

Adjusted
OR

Metabolite

Wald
p-value

Table 3.3 Logistic regression parameter estimates and odds ratios of metabolites included in
the final predictive model. Significant metabolite predictors are indicated in bold and are in
good agreement with results from the two-sample t-tests. Exponentiation of parameter
estimates gives their corresponding odds ratios (OR). An OR greater than 1 indicates that for a
given unit increase in the specified metabolite within a sample, there is also an increase in the
probability of the tissue sample being high spiking. In contrast, OR less than 1 indicates
decrease in the likelihood that a tissue sample is high spiking for a unit increase in the specified
metabolite. Adjusted OR are odds ratios calculated for every 0.1 increment of a metabolite
instead of the standard 1.0 increment used to calculated standard OR. It is important to note
that the odds ratios are multiplied by for every unit increment in the predictor (i.e. metabolite
levels) due to the exponential nature of logistic regression. For example, in the case of choline,
a 0.20 unit increase in choline reduced the odds of the tissue being high spiking by a factor 0.26
(i.e. 0.51 × 0.51 = 0.26) (* p < .05, ** p < .01, *** p < .001)
In order to better understand the significance of these findings, we performed an
integrative analysis of metabolomic, transcriptional, and histological measures from each of the
18 brain samples, as outlined in Figure 3.1. Two major clusters of gene-metabolite interactions
emerged, centering on changes in energy state, with a down regulation of lactate and
upregulation of Cr+PCr (Figure 3.5). Down-regulated lactate clustered with a group of genes
associated with G-protein coupled receptor (GPCR) signaling and angiogenesis pathways (FDR
adjusted p < 0.01), specifically VEGFA, FLT1, RGS1, RGS2, RHOU, GNA13, and TFRC, all of
which were up-regulated in high-spiking brain regions. Also notable from the cluster was the
upregulation of multiple genes associated with ubiquitination, highly suggestive of the
preferential involvement of the ubiquitin-proteasome pathway (UPP) in high spiking areas.
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Using a larger set of brain samples, some of which were included here, we developed a
novel clustering approach to predict cell-type specific changes in regions of high versus low
epileptic spiking, creating what we called a “cellular interactome” (Dachet et al., 2015). In that
study, we showed consistent differences in high spiking tissues that included increases in blood
vessel density, inflammatory microglia, and millimeter-sized microlesions in deeper cortical
layers. These microlesions contain a unique population of neurons with reduced NeuN staining
(Type 1 Neurons) and increased microglia (Type 1 Microglia).

Combining the cellular

interactome with the present metabolomic dataset, we found significant correlations between
reduced lactate and Neuron 1 (r = 0.76; p < 0.05) and increased Cr+PCr and Microglia 1 (r =
0.72; p < 0.05) (Figure 3.6A-B). Both cell populations correlated with the degree of epileptic
activity and the number of microlesions (Dachet et al., 2015). Histological examination of the
specific tissue samples used here consistently showed the increased presence of microlesions and
increased vascular density in high versus low spiking regions (Figure 3.6C). Taken together the
combined genomic-metabolomic and cellular interactome suggests the existence of a unique
signature linked to altered tissue energy demand and consumption in high spiking brain tissue
that could serve as a clinically translatable, non-invasive biomarker for the functional and
structural abnormalities that underlie human neocortical epilepsy.
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Figure 3.5 Correlational clustering between predictor metabolites and differentially expressed
genes in high spiking tissues demonstrate a large cluster of up-regulated genes around lactate, a
negative predictor of high spiking. Upregulated genes are indicated in green and downregulated
genes are indicated in red. Pathway enrichment analyses indicate many of these differentially
expressed genes to be involved in G-protein signaling, angiogenesis as well as ubiquitination.
Relevant genes in the lactate cluster include: VEGFA, FLT1, RGS1, RGS2, RHOU, GNA13,
PK3CA, and TFRC.
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Figure 3.6 A) Hierarchical clustering between metabolites and cell types show significant
associations between lactate and Neuron Type 1 (Neuron 1) and also between Cr+PCr and
Microglia Type 1 (Microglia 1). The red line indicates significance threshold of correlation,
where paired relationships to the right of the line are significant. B) Normalized expression over
all 18 samples between Lactate and Neuron Type 1 and between Cr+PCr and the cluster
consisting of Microglia Type 1 and several other cell correlational clusters show stronger
clustering between lactate, Cr+PCr and several cell types with the correlations between
Microglia Type 1 and Neuron Type 3 being significant (solid lines). Other correlations in the
same cluster, while not statistically significant, are also shown (dashed lines). C) Representative
histology from Patient 1 demonstrating increased blood vessels and the presence of microlesions
(outlined) showing reduced NeuN staining in high spiking tissue compared to its low spiking
counterpart.
3.5 Discussion
Epilepsy has been a challenging disease to diagnose and develop novel treatments for due
to limitations in non-invasive methods to identify epileptic brain regions. Scalp EEG recordings
can reliably detect epileptic discharges occupying at least 10 cm2 of brain tissue (Tao, Ray,
Hawes-Ebersole, & Ebersole, 2005).

1

H MRS, with its ability to simultaneously measure

multiple metabolites, offers a potentially powerful means to detect epileptic brain regions. While
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previous 1H MRS epilepsy studies have focused on epilepsy associated differences in individual
metabolites or the ratios of a few metabolites, changes in the entire metabolite profile, as
demonstrated by our findings here, could be informative for the development of high resolution
brain maps of epileptic activities. The unique metabolomic-genomic differences discovered here
for high-spiking epileptic human brain suggest that high spiking regions of the neocortex have a
unique metabolic and energetic signature that could enable non-invasive 1H MRS approaches to
differentiate these brain regions from their normal counterparts.
The systems biology approach applied here linking human brain electrical activity to
metabolomics, genomics, and cellular/histological changes offers a powerful, unbiased approach
to discover and simultaneously validate biomarkers of human epileptic brain. Hierarchical
clustering between metabolites and cellular changes, as defined by their transcriptional profile,
showed a close parallel between the down-regulation of both lactate and Type 1 Neurons. This
was validated through the identification of reduced NeuN staining within microlesions that we
found to be present in high numbers in human cortical epileptic brain regions (Dachet et al.,
2015). Similarly, the upregulation of Cr+PCr correlated with an increase of other neurons and
Type 1 Microglia. Interestingly, microglia have also been shown to express high levels of PCr
(de Gannes, Merle, Canioni, & Voisin, 1998), which may help explain Cr+PCr as a positive
predictor of high spiking activity.
Exactly why lactate is consistently downregulated in these brain regions is not clear.
This may be due to unmet energy demands due to frequent IEDs leading to lactate consumption
as an alternative energy source. While one would expect surgically excised tissue to become
hypoxic and increase lactate levels, our unique study design using multiple paired samplings of
both high and low spiking samples from within the same patient should control for this. Recent

38
work has shown that inhibition of lactate dehydrogenase, the key enzyme that coverts lactate to
pyruvate for use in the TCA cycle, can cause hyperpolarization in neurons and suppress
epileptiform activity (Sada, Lee, Katsu, Otsuki, & Inoue, 2015).

The strong correlational

relationship between lactate and the cluster of genes enriched in angiogenesis is further validated
by histological evidence of blood vessel proliferation in high spiking samples and may be a
compensatory reaction to higher energy demands (Dachet et al., 2015). Selective involvement of
angiogenesis factors in high spiking regions also hints at the potential role of anti-angiogenesis
therapies as a potential mean to combat epileptogenesis. Indeed, Morin-Brueau and colleagues
have recently carried out studies on the interaction between epileptiform activity and
angiogenesis in rodent hippocampal cultures (Morin-Brureau et al., 2011). The results of their
studies suggest that that targeted inhibitors of one or more downstream pathways associated with
VEGF could be used potentially to treat epilepsy (Morin-Brureau et al., 2011; Morin-Brureau,
Rigau, & Lerner-Natoli, 2012). More over, there is evidence for disrupted blood brain barrier
(BBB) associated with VEGF overexpression in patients with intractable temporal lobe
epilepsies (Morin-Brureau et al., 2011; Rigau et al., 2007), potentially allowing for the use of
novel therapeutic agents that would have limited penetration through otherwise intact BBBs.
Contrary to what is most often reported in literature where NAA ratios with creatine or
choline moieties are typically decreased in epileptic regions (Bernasconi et al., 2002; Breiter et
al., 1994; Cendes et al., 1997b; Connelly, 1997; Matthews et al., 1990), NAA was not a
significant predictor of high versus low spiking in our regression model. Levels of NAA
between high and low spiking tissue samples were also not significantly different based on the
results of our two-sample t-test. We suspect localization and partial volume effects to be major
causes of this discrepancy. While vast majority of studies in literature specifically studied the
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hippocampus or portions of the temporal lobe, we were very precise about using only the
superficial layers of the neocortex for our HR-MAS 1H MRS study, given that was where most
of the transcriptional changes associated with MAPK/CREB activation were seen. Furthermore,
1

H MRS studies of neocortical epilepsy generally study metabolite differences between various

regions of the brain where the ROIs typically include mixtures of both gray and white matter.
Given the role that NAA is also known to play in myelin lipid synthesis (Chakraborty, Mekala,
Yahya, Wu, & Ledeen, 2001; Mehta & Namboodiri, 1995), contributions of white matter NAA
to the signal could lead to very different findings compared to NAA signals derived specifically
from gray matter.
A key feature of these epileptic brain regions is the presence of microlesions that show
dramatic, focal reductions in synaptic connectivity (Dachet et al., 2015). Consistently, the
involvement of both choline and GPC in our predictive model suggests heightened cell
membrane turnover in high spiking tissue. GPC and free fatty acids (FFA) are key breakdown
products of phosphatidylcholine (Podo, 1999), a major membrane constituent. This breakdown
process can be initiated under hypoxic conditions with the calcium-dependent activation of
phospholipase A2 (PLA2), which is also responsible for the release of arachidonic acid, a potent
inflammatory intermediate (Farooqui, Yang, Rosenberger, & Horrocks, 2002). Furthermore, in
recurrent seizures, cortical oxygenation level has been show to be inversely related to FFA
release (Visioli, Rihn, Rodriguez de Turco, Kreisman, & Bazan, 1993). Choline, also a key
component in membrane turnover, is active both as a membrane precursor and as a membrane
breakdown product from GPC degradation. Given the comparative lack of free choline despite a
relative increase in GPC in high spiking tissue, we suspect a re-distribution of choline into
various anabolic pathways, such as regeneration of phosphatidylcholine for new membrane
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synthesis or acetylcholine synthesis. In fact, elevated acetylcholine receptor activation is known
to increase seizure potential (Priel & Albuquerque, 2002). Pilocarpine, an acetylcholine receptor
agonist, is a relatively common agent used to generate seizures in animal models (Cavalheiro et
al., 1991; Pitkänen, Schwartzkroin, & Moshé, 2005).
The ability of metabolite profiles to predict accurately whether or not a given tissue
sample is high or low spiking is remarkable and is a clear reflection of the distinct metabolic
environments associated with persistent epileptiform activity. The metabolites outlined in our
predictive model demonstrate that 1H MRS is capable of accurately distinguishing epileptic from
non-epileptic regions. With further technical refinement, these metabolites may be adapted for
clinical use and become an invaluable tool in our efforts to better understand and treat epilepsy
and the underlying processes leading to the disorder.
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CHAPTER 4: LONGITUDINAL METABOLITE CHANGES IN A MRI-COMPATIBLE
ANIMAL MODEL OF IED AND EPILEPTOGENESIS
4.1 Summary
The clinical nature of epilepsy is such that the vast majority of patients presenting to a
clinician will have already suffered at least one seizure episode, and are well on their way toward
having an established epileptic condition. This inability to identify patients prior to seizure onset
makes the use of a molecularly accurate animal model of epileptiform activity invaluable for the
study of IEDs during epileptogenesis. Here, we developed a MRI-compatible EEG monitoring
system in a rat animal model of IEDs and seizure development to study longitudinal metabolite
changes in the rat cortex using 1H MRS at 7T. The observed metabolite changes in this study are
suggestive of energy imbalance in the anterior regions of the rat brain. Involvement of Cr+PCr
and GPC+PCh recapitulates similar findings in our ex vivo human study presented in Chapter 2.
These results provide evidence that 1H MRS can be a sensitive technique for detecting metabolite
changes associated with epileptogenesis.
4.2 Introduction
As discussed in Chapter 1, the exact relationship between IEDs and seizures is not well
understood. IEDs in the form of interictal spiking activity on electrophysiology are frequently
used to assist in the identification of seizure onset regions and the removal of both high spiking
and seizure onset regions tends to yield the best treatment outcome (Asano et al., 2003; Bautista
et al., 1999; Kanazawa et al., 1996; Lee et al., 2014). They also occur more frequently than
seizure episodes, potentially making them a more sensitive marker of neuronal and metabolic
dysfunction or of underlying disease progression than seizure frequency. Animal studies have
shown that interictal activity may precede the development of seizures with a positive correlation
between the frequency of spikes and rate at which epilepsy tend to develop in these animal,
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making them a potential biomarker of seizure development (White et al., 2010). Here, we plan
to study the temporal and spatial associations between IED frequency and metabolite changes as
detected by 1H MRS at 7T in a longitudinal rat model of epileptogenesis with spontaneous and
persistent IEDs.

This study will also directly assess whether there are metabolite profile

differences between animals treated with tetanus toxin and those receiving vehicle injections.
This study can also serve as an important in vivo validation of our previous ex vivo human tissue
study (Chapter 3).

Consistent metabolite changes common to both studies could indicate

biomarkers that may be used to detect both established epilepsy and epileptogenesis.
The identification of metabolite biomarkers ex vivo in epilepsy patients (Chapter 3) is an
important first step in the development of non-invasive biomarker for epilepsy in humans.
However, the question remains whether these metabolite biomarkers may be used to identify
metabolite correlates of IEDs or ideally epileptogenesis in vulnerable populations prior to the
onset of established epilepsy.

Animal models may be an invaluable tool to study these

metabolite changes over time and their underlying biochemical changes. The ideal animal model
would closely resemble epilepsy in humans with a non-symptomatic prodromal phase followed
by chronic and spontaneously generated seizure episodes and recognizable paroxysmal IEDs
even in the absence of concomitant seizures.

Treatments and methods used to induce

epileptogenesis should not result in significant neuronal toxicity or cell death (Barkmeier &
Loeb, 2009).
Many models of epilepsy exist and they may be classified into two categories: 1) acute
versus chronic models and 2) hippocampal versus neocortical. Acute models such as those using
penicillin can induce IED and epilepsy like behavior in a matter of hours, and can be a good
choice for studying behaviors associated with epilepsy or mechanisms associated with the spread
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of systemic seizures (Rubio, Rubio-Osornio, Retana-Márquez, Verónica Custodio, & Paz, 2010).
Unfortunately, it is difficult to determine whether the mechanism underlying these acute changes
are similar to the mechanisms underlying chronic changes seen in human epilepsy patients. For
this reason, chronic models, with their distinct latent period prior to the development of
spontaneous seizures (Pitkänen et al., 2005), are preferred over acute models for studying
epileptogenesis. Most of the common chronic models for epilepsy such as kindling or systemic
injections of pilocarpine or kainic acid, affect the limbic system in a manner that parallels human
temporal lobe epilepsies more than neocortical epilepsies (Sarkisian, 2001), and frequently cause
significant neuronal damage to the hippocampus. Tetanus toxin and heavy metals such as zinc
and cobalt are the two primary models used for modeling chronic neocortical epilepsies
(Barkmeier & Loeb, 2009). Of the two, only tetanus toxin does not cause extensive tissue and
neuronal damage when directly applied to the cortex, which is an important for our studies since
we are interested in identifying biomarkers that reflect the physiologic basis of epilepsy rather
than tissue injury. Tetanus toxin works by transiently inhibiting the release of GABA from
inhibitory interneurons with a simultaneous increase in the release of excitatory
neurotransmitters (Williamson, Fitzgerald, & Neale, 1992). Injection of the toxin directly into
the somatosensory cortex has been observed to primarily result in IEDs (Brener, Amitai,
Jefferys, & Gutnick, 1991) with relatively infrequent seizures that develop over the course of
days to weeks (Nilsen, Walker, & Cock, 2005) and can persist to upwards of 7 months (Brener et
al., 1991). For the purposes of our study, tetanus toxin offers the combination of features most
suited for our longitudinal study of IED and epileptogenesis in a chronic setting with minimal
neuronal damage.
Further characterizations of the tetanus toxin rodent model by our laboratory revealed
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many similarities to human epilepsy (Barkmeier et al., 2012). In this model, IEDs were noted to
appear within a few days after treatment and increases in frequency over time with few
associated seizures. Similar to human epilepsy (Beaumont et al., 2012), a similar pattern of
activated CREB and induction of plasticity genes in layers II/III of the cortex was observed.
Blocking of MAPK signaling using a selective MAPK inhibitor attenuated the layer II/III CREB
activation and reduced frequency of observed IEDs without affecting seizures (Barkmeier et al.,
2012). These findings suggest that this model can accurately recapitulate the molecular and
electrophysiological features of epilepsy and may be a useful model for studying IED and its
relation to epileptogenesis and may also be a good model system for testing efficacy of novel
therapeutics.
For this study, we use 1H MRS at 7T to longitudinally study the changes in metabolites
over time in our tetanus toxin rat model. Concurrent electrophysiology studies that provide
information on IED frequency and progression over time is measured using an implantable MRIcompatible intracranial EEG recording system developed for this animal model. The main aim
of this study is to identify both temporal and spatial changes in potential metabolite biomarkers
associated with epilepsy development and how these metabolites may relate to IED activity in
these animals. Given the molecular similarities observed in this animal model and in human
epilepsy, we hypothesize that we will identify changes in energy balance and synaptic plasticity,
similar to what was found in our study of human epilepsy tissue ex vivo (Chapter 3).
4.3 Methods
4.3.1 Rodent surgery, tetanus toxin injection, and electrode implantation
All studies were carried out on 4 month old male Sprague-Dawley rats (n = 16) split into
3 groups: tetanus injected treatment group (TET; n = 7) and vehicle injected positive control
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Figure 4.1 Four recording electrodes
and one reference electrode were
secured directly to the rat skull.
Electrode channels are numbered
numerically
from
anterior
to
posterior and left to right. Electrode
placements are indicated by closed
circles and were based on distances
from the bregma (Paxinos & Watson,
2007). Tetanus toxin was injected
into the burr hole drilled for the
placement of Channel 2 recording
electrode (red closed circle).

group (CTL; n = 5) and normally
developing controls with no surgery
(NCT; n = 2). Each rat was implanted with 5 MRI-compatible silver recording electrodes: 2 on each
hemisphere plus 1 reference electrode over the nasal sinus (Figure

4.1). The selection of electrode material was given extra consideration due to the strong magnetic environment the electrodes would be subjected to. Silver was selected as the primary
material of choice due to its malleability, ease of fabrication, biological inertness, is a
diamagnetic material, and also has a relatively low susceptibility, a measure of how a particular
material would distort its surrounding magnetic field ( χ silver = −24 ×106 compared to

χ stainless steel = 3520 to 6700 ×106 and χ calcium = 21.7 ×106 ) (Schenck, 1996).

Each electrode is

constructed from multi-stranded silver wires with PTFE coating (Medwire Corporation, Part
#AG7/40T, Mount Vernon, NY) and soldered to a size 1-64 hand-tapped silver screw. The silver
recording screw is then chlorided in a saline bath using a pure silver anode with a 1.5 V battery
source for 2 minutes (Ives, 2005) to create a Ag/AgCl electrode which, known to have improve
recording characteristics compared to Ag electrodes (Geddes & Baker, 1967).
One day prior to surgery, rats were placed on an initial dose of liquid acetaminophen in
their drinking water (2 mg/mL of water). General anesthesia was induced using ketamine (80
mg/kg IP) and xyalzine (13 mg/kg IP) combination. Once an adequate plane of anesthesia was
confirmed by the absence of a toe pinch reflex, the incision area along the dorsal surface
extending from the head to the upper torso of the animal, were shaved and cleaned with betadyne
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and ethanol.

Ophthalmic ointment and lidocaine gel were placed onto the eyes and ears,

respectively, for protection prior to being placed on the stereotaxic frame. Adequate plane of
anesthesia was checked approximately every 5 minutes during surgery and an additional ½ dose
of ketamine/xyalzine was administered when necessary to maintain anesthesia.

Figure 4.2 Surgical implantation of recording electrodes and exteriorization of the connector. A)
Drilled burr holes do not penetrate dura with the exception of the injection site where a Hamilton
needle was stereotaxically advanced into the somatosensory cortex, through the dura. Electrodes
are then screwed directly into the skull after injection and secured with dental cement. B) EEG
connector was exteriorized to the region between the animal’s shoulder blades to accommodate
placement of the surface head coil during MR sessions.
Once the skull had been adequately exposed, five holes were drilled (Figure 4.2A)
through the full thickness of the skull without penetrating the dura. The stereotactic injection is
delivered into the left somatosensory cortex (AP -1 mm, L 3.5 mm relative to bregma, depth 1.5
mm) (Paxinos & Watson, 2007). TET animals received tetanus toxin (Sigma, Catalog #T3194; 1
µL at 100 ng/µL in 0.01 M sodium phosphate) into the left somatosensory cortex while CTL
animals received vehicle (1 µL 0.01 M sodium phosphate). Injections were made with a blunt
tipped Hamilton syringe advanced 1.5 mm into the cortex over the course of 4 minutes and the
needle was left in place for 10 minutes prior to retraction from the brain. The bilateral recording
electrodes (AP +4 mm, -1 mm , L 3.5 mm relative to bregma) were screwed directly onto the
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skull and secured with dental cement.

The electrodes were exteriorized to back-mounted

connectors (Plastics One Inc., Roanoke, VA) (Figure 4.2B) to accommodate surface coil
placement during MR sessions while allowing the animal to maintain mobility during EEG
recording sessions.
All incisions were closed and secured with nylon sutures and triple antibiotic ointment
(TAO) was applied. The entire surgical procedure typically required 30-45 minutes from
anesthesia induction to transferring the animal from the stereotaxic frame to a recovery chamber
with a suitable heating source. They were injected with 10 mL of lactated ringer’s solution
subcutaneously and left undisturbed until they have recovered from the anesthesia, at which
point they would be transferred to animal housing facilities. Liquid acetaminophen was provided
in their drinking water (2 mg/mL of water) for a period of five days and TAO was applied daily
for three days after surgery. Sutures were removed approximately one to two weeks after
surgery, when the incisions have healed adequately. EEG recordings were made using Stellate
Harmonie video EEG recording system sampling at 200 Hz every other day starting on day 7
after surgery. During recording, animals were placed into a clear-walled recording chamber for
2-3 hours. Recordings were typically done between 9 AM and 1 PM to minimize circadian
rhythm effects.
4.3.2 1H MRI/MRS Assessments
Bi-weekly 1H MRI/MRS scans over 6 weeks were done on a 7 Tesla Bruker ClinScan using
a 2-channel phased array receive-only surface coil. For anesthesia induction, the animal was
placed in a 1L induction chamber containing 2.0-4.0% isoflurane mixed with medical air
connected to an isoflurane-scavenging filter. Induction typically took 5-10 minutes and was
considered complete when the animal exhibits loss of righting reflex along with loss of toe pinch

48
reflex.

The animal was then quickly transferred to the MR scanner and maintained on

maintenance isoflurane (2% isoflurane mixed with medical air). Adequate body temperature was
also maintained for the duration of the scan using warm circulating water (37°C) and the
animal’s core temperature was monitored between scan sequences, approximately every 10 to 15
minutes using a fiber optic rectal probe. A rapid drop in core temperature (> 1°C) or evidence of
excessive motion on MR scans were signs of physiological stress and were causes for immediate
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Figure 4.3 Timeline of study. Initial baseline scan (MRS (a)) occurred 4 days prior to surgery.
Surgery was performed on day 0. First EEG recording session typically took place on day 7
depending on the animal’s recovery progress. First MRS evaluation took place on day 10 (MRS
(b)) and repeated every 2 weeks until end of study at day 38.
Initial scout image followed high resolution axial, sagittal, and coronal T2-weighted images
were collected to assist in voxel placement. Major landmarks and voxel positions were observed
and recorded to maximize the consistency of measurements between time points. Single voxel
spectroscopy of both water suppressed and fully relaxed water unsuppressed signal were
collected using PRESS (Point Resolved Spectroscopy) with the following sequence parameters:
TE = 14 ms, TR = 3500 ms, 256 averages, spectral bandwidth = 3500 Hz, 2048 points. Each
measurement was carried out in a 3.0 × 3.2 × 2.0 mm3 voxel, placed in the neocortex, adjacent to
the location of a recording electrode of interest (Figure 4.6A).

1

H MRS measurements were

performed every two weeks starting with an initial baseline assessment at four days prior to
surgery (Figure 4.3).
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4.3.3 1H MRS quantitation
Quantitation of raw 1H MRS was done using LCModel (Provencher, 1993) with a simulated
TE = 14 ms basis set consisting of 17 individual metabolites along with 8 simulated
macromolecule resonances.

Concentration of metabolites between 0.2 to 4.0 ppm were

estimated, normalized to total tissue water obtained from unsuppressed water signal, and
expressed in units of mmol/kgwet weight (Provencher, 2014). The full list of metabolites used for
fitting in this study is provided in Appendix A. As described in Chapter 3, LCModel provides
CRLB estimates as indicators of how confident the fitted metabolite spectra matches the original.
For the purposes of this study only metabolites and their ratios with CRLB values less than or
equal to 10% were retained for further analysis.
4.3.4 IED quantification
Final quantitation of IEDs were carried out in using an automated in-house Matlab (The
MathWorks, Inc., Natick, Massachusetts, United States) script that was a modified version of an
existing program (Barkmeier et al., 2011) with several key features added: 1) wavelet based denoising and signal fitting 2) Lowess spline baseline subtraction, and 3) multi-channel spike
detection. Conventional frequency filters, such as the Butterworth filter will typically introduce
a phase shift in the time dependent signal, which if uncorrected for, can cause a distortion of the
final waveform (Figure 4.4). Unfortunately, most programs do not properly compensate for this
phase shift, resulting in a distorted waveform such that true spikes may be shifted inappropriately
out of phase and go unnoticed by the algorithm or noise may be shifted inappropriately to
resemble a spike and be marked as a false-positive spike. Lowess spline baseline subtraction was
implemented as a means of removing non-periodic slow moving changes in the baseline of the
EEG signal frequently present in the reference montage (i.e. electrode signal minus reference
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signal) and was used in the calculation of spike parameters such as peak base width and AUC.
The original spike detection program only marked spikes in the channel with the highest
amplitude without explicitly recording spike spread into nearby channels. The added feature of
multi-channel spike detection allowed us to determine the frequency and manner by which IEDs
can spread through the cortex in the form of propagating spikes across electrodes.

Figure 4.4 Wavelet based de-noising and waveform fitting. A) Conventional frequency filters,
such as the Butterworth, can result in phase shifts in the time signal, leading to distortions that
can be misinterpreted, as shown by the EEG trace labeled “Bandpass (1-35 Hz).” Wavelet based
de-noising does not suffer from this issue and is able to effectively eliminate noise and produce a
clean “fit” of the signal (red overlay). B) Subtraction of the estimated baseline obtained (thin
grey line running through the signal in the trace labeled “Raw Fit Baseline”) from using a
Lowess fit eliminated low frequency noise and allowed for uniform characterization of spikes.
Shaded rectangles indicate potential spikes that can be marked by the algorithm.
Prior to EEG analysis using the automated spike detection algorithm, periods of
excessive motion by the animal, visually identifiable as large amplitude motion artifacts, were
marked manually and the spike detection algorithm was programmed to skip those marked
sections to speed up the detection process, as spike detection is impossible in the presence of
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those artifacts. Only segments of no motion
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detection algorithm is given in Figure 4.5.
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Figure 4.5 Flow chart of EEG data
processing and spike detection

wavelet
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using

Battle-Lemaire

Spike detections are carried out in each
channel consecutively after wavelet denoising and baseline subtraction. EEG data

on each channel is split into a series of 10 minute blocks and processed in parallel using Matlab’s
native Parallel Processing toolbox. A high percentage of high amplitude noise in the block

(

)

relative to the signal’s median absolute deviation, or MAD ( MAD = median xi - median(xi ) )
was indicative of excessive noise, causing the whole block to be rejected. Determination of a
positive spike was based on three key criteria evaluated by the algorithm: 1) spike peak height
must exceed twice the standard deviation (SD) of the signal relative to the baseline, 2) troughs of
the spike must be at least 1 SD below the baseline, and 3) peaks must be between 50 ms to 200
ms in duration. Following spike detection, all identified spikes and their key features such as
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location, amplitude, and AUC were tabulated onto a data table in addition to being annotated
directly onto a copy of the original EEG file for manual validation and visualization.
4.3.5 Statistical analysis
Several repeated measures mixed GLM regression models were used to analyze both 1H
MRS and IED time series data. Several mixed models were used to determine the effects of
TIME (Weeks 1 through 5), TREATMENT (CTL and TET), and their interactions (Equations
3.1–3.2) on several electrophysiological parameters including hourly spike count for single
spikes, hourly spike count for spreading spikes, amplitude, and AUC. Where appropriate, a log
link function was used to analyze the IED time series data, which was represented in spike
counts per hour (Poisson distribution) averaged into weekly bins. Otherwise, an identity link
function was used for non-count data.

$
'
ln(SPIKES)*=*β0 *+*β1 × TIME*+*β2 × TREATMENT*+* & b0 *+∑ biZi )+*ε
%
(
i
$
'
ln(SPIKES)*=*β0 *+*β1 × TIME*+*β2 × TREATMENT*+*β3 × TIME× TREATMENT*+* & b0 *+∑ biZi )+*ε
%
(
i

(Equations 3.1 – 3.2)
To account for rat aging effects during the study, the time course data for the NCT
animals were averaged at each time point and systematically subtracted from both of the TET
and CTL groups for each metabolite. A similar set of repeated measures mixed models were
used to study the effect of TIME (time points: b, c, d), TREATMENT (CTL and TET), as well as
their interactions on the various metabolites (Equations 3.3–3.4). Time point “a” was not
included in the model since it was an initial baseline measurement for the animals prior to any
surgery or treatment. A complementary verification analysis was also performed using original
MRS data not adjusted for aging effects (i.e. average metabolite levels for NCT animals were not
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subtracted from TET and CTL groups at each time point) to assess the robustness of the
moderation effect that TREATMENT has on the metabolites over time.

$
'
METABOLITE)=)β0 )+)β1 × TIME)+)β2 × TREATMENT)+) & b0 )+∑ biZi )+)ε
%
(
i
$
'
METABOLITE)=)β0 )+)β1 × TIME)+)β2 × TREATMENT)+)β3 × TIME× TREATMENT)+) & b0 )+∑ biZi )+)ε
%
(
i
(Equations 3.3 – 3.4)
All models were analyzed in R (Team, 2014) using lme4 package (Bates, Mächler,
Bolker, & Walker, 2015). Individual animals were included as the random effect to control for
within-subject effects. Analyses were stratified both for metabolite and region. The threshold
for significance was specified at p < 0.05. Unless otherwise stated, all reported significance
values were uncorrected for multiple comparisons. In situations where multiple comparison
corrections were implemented, a FDR adjusted p < 0.05 was considered significant.
4.4 Results
On average, each animal had approximately 45 minutes of motion-free EEG recordings
per recording session that could be used for automated spike analysis. Each animal had 3 to 4
EEG recording sessions per week over the entire study duration. The quality of the acquired 1H
MRS signals is generally very high with clear separation of major metabolite peaks (Figure
4.6B). LCModel estimated SNR for the dataset was 11.2 ± 3.8 (mean ± s.d.). Similar to our
human tissue ex vivo study (Chapter 3), only metabolites with mean CRLB of less than or equal
to 10% were used for analysis. These metabolites were: Gln, Glu, m-Ins, NAA, Tau, simulated
macromolecule at resonance position 0.9 ppm (MM09), GPC+PCh, Cr+PCr, NAA+NAAG, and
Glu+Gln.
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Figure 4.6 Single voxel placement and sample spectra A) Placement of voxels (green rectangle)
in relation to recording electrode (yellow closed circles). Location of tetanus or vehicle injection
is indicated by open red circle. The location of the axial slice shown in lower panel is indicated
by white dashed line in the upper panel. Dashed yellow rectangles indicate location of recording
electrode in the skull. B) Representative high quality spectra were obtained from voxel regions 1
and 2 (upper and bottom panels) respectively.
There was a significant decrease in spike rate over time in all of the regions (Figure 4.7AB), although effect of TREATMENT appears to only have a significant influence on the anterior
electrodes, where CTL animals seem to be showing increased spiking activity.

The

TREATMENT main effect seemed to have little influence in the posterior electrodes. Channel 3
was the only electrode to consistently show a moderating effect by TREATMENT, precipitating
a faster rate of decline in spike counts in the CTL group compared to the TET group. Comparing
anterior channels (Channels 1, 3) directly to posterior channels (Channels 2, 4) revealed that
anterior channels exhibited significantly more spikes and TREATMENT appeared to have a
moderating effect on the rate of spike decrease. Other measures of spike properties such as AUC
and amplitude also showed a significant decrease over time irrespective of treatment group, with
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the exception of Channel 3, where the CTL group showed higher amplitude and AUC and a
faster decline in those measures over time compared to the TET group (Figure 4.7C-D).
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Figure 4.7 No clear difference in spiking over time between tetanus treated and control animals.
All electrodes showed significant decreases over time in all 4 measures of interictal spiking:
single spike hour count (A), spreading spike hourly count (B), amplitude (C), and AUC (D), with
the right anterior electrodes (Channel 3) consistently showing a significant treatment effect in
both the number of spikes and the rate of spike count decline.
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Figure 4.8 Metabolite dynamics over time. A) In general, CTL animals had fewer metabolites
that changed significantly over time, with NAA+NAAG being the only metabolite to survive
multiple comparison correction. B) TET animals had 7 metabolites that changed significantly
over the study period. Most of the metabolite changes were observed in the anterior half of the
rat brain. C) Glu, Tau, GPC+PCh were the only metabolites that were significantly moderated
by the effect of TREATMENT over the study period, with Gln being the only metabolite to
survive multiple comparison correction. The changes in Cr+PCr also appear to be affected by
treatment group, although the effect was not statistically significant (p < 0.07). D) MRI
localization of rat brain with voxel placement for reference has following regional designations:
voxel 1 (left anterior), voxel 2 (left posterior), voxel 3 (right anterior), voxel 4 (right posterior).
Arrows in panels A-C indicate direction of metabolite difference or rate of change in TET
animals relative to CTL animals.
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Figure 4.9 Changes in several metabolites over the study period are moderated by treatment
group. Several metabolites in the TET group are observed to increase significantly over time
while levels in the CTL group remained steady within the left anterior region: Tau (A), GPC (B).
Cr+PCr also shows a similar pattern of increase, but the rate of change did not reach statistical
significance at the specified cutoff. Gln levels in TET group significantly decreased over time
while CTL group also remained unchanged (D). Metabolite concentrations in mmol/kgwet weight
were normalized to tissue water and expressed as the difference from mean metabolite levels for
NCT animals at each corresponding time point. Reported significance values are unadjusted for
multiple comparisons. N.S. indicates p > 0.05.
Metabolite expression profiles over time were very different between our CTL and TET
groups (Figures 4.8-4.9). Comparing the metabolite profiles between the two groups directly,
the TET group was much more dynamic than CTL in that 7 different metabolites or their
combinations were noted to have significant changes over time in the TET group (Figure 4.8B)
while only a single metabolite, NAA+NAAG, was noted to be significantly increased over the
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study period in the CTL group (Figure 4.8A). It is interesting to note that the majority of
dynamic metabolites were observed in the anterior regions of the brain, where the spike counts
were also persistently higher.
Several significant TIME×TREATMENT interactions were also noted for several
metabolites in the anterior half of the rat brain (Figure 4.8C). The TET group was more likely to
see progressive increases in Tau and GPC+PCh in the left anterior regions of the rat brain, while
the CTL group was more likely to remain unchanged. We also observed a similar behavior with
respect to Cr+PCr, although the interaction did not reach statistical significance (p < 0.07). A
significant decline in Gln over time in the TET group compared to an unchanged CTL group was
also noted in the right anterior region of the rat brain (Figure 4.9).

These findings were

replicated in our verification analysis using MRS data unadjusted for aging, which similarly
showed a preferential decrease in Gln (right anterior region; p < 0.001; FDR adjusted p < 0.01)
and preferential increases in Tau (p < 0.01), GPC+PCh (p < 0.05), and Cr+PCr (p < 0.05) in the
left anterior region of TET animals compared to CTL animals.
4.5 Discussion
The natural extension of our human tissue ex vivo study is to determine if similar
metabolite changes may be visualized in our rat model longitudinally.

Tracking the

electrophysiological changes in these animals over the study period becomes extremely
important, as spontaneous IEDs generally have no associated physical manifestations that could
be easily observed (Gibbs, 1936). The major challenge of this study was to design a set of MR
compatible EEG electrodes capable of recording signals for a minimum of five weeks. In many
respects, this study was just as much of a test for the design of a durable, MR compatible, long
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term intracranial EEG recording method as it was for identifying relevant metabolite biomarkers
of epilepsy development.
While the existing non-MR compatible recording setup used by our laboratory has been
able to record a progressive increase in IED frequency in tetanus treated animals over the course
of several weeks (Barkmeier et al., 2012), this study was unable to replicate those findings.
However, the electrophysiology obtained from this study does implicate several major
contributing factors that could have led to such different results and point to changes that may be
made to improve the procedure in future designs.
First, the progressive attenuation of signal amplitude over time, likely due to oxidation of
the electrode tip, with the most severe attenuation seen after the first three weeks of recording,
suggests that silver electrodes may not be appropriate for the long term application necessary
here. While long term EEG electrodes using silver had been developed for clinical environments
and tested successfully over the duration of several days (Ives, 2005), little information was
available on how similarly implanted electrodes would perform over the course of several weeks
in a biological system. Results from our study indicate that recording sensitivity was severely
attenuated after 2 to 3 weeks post-implantation. Other MR compatible materials such as carbon
fiber, gold, or platinum-iridium alloys (Jupp, Williams, Tesiram, Vosmansky, & O'Brien, 2006;
Mirsattari, Sharpe, & Young, 2004) should be considered for future studies.
Second, the exteriorization of the recording connector to the scapular region, while
purposefully done to accommodate the MR surface coil placement above the animal’s head, also
made the recordings much more sensitive to environmental noise as extra lengths of wires had to
run subcutaneously from where the electrodes were secured on the skull to the connector at the
scapula. The introduction of extra environmental noise lead to exclusion of a significant portion
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of the EEG recording (inter-quartile range: 30% to 86% exclusion) and also increased likelihood
performance errors by the spike detection algorithm. A better approach perhaps would be to
customize the surface coil architecture to accommodate the design of the EEG connector (Van
Audekerkea, Peeters, Verhoye, Sijbers, & Van der Linden, 2000), which ideally would have
been secured directly onto the cranium.
Finally, 1H MRS places a great demand on the homogeneity of the magnetic field in order
to produce excellent spectral resolution. Introduction of any foreign object or material will cause
a distortion in magnetic field, and the degree of distortion will depend heavily on the properties
of the material being introduced. Depending on the research question being emphasized and
whether or not the end goal is to detect sensitive metabolite biomarkers, an argument could be
made to split the animal model into two parallel cohorts. One cohort for performing standard
EEG electrophysiology with and without tetanus toxin injections and a separate cohort with no
electrodes implanted used specifically for 1H MRS studies, also with and without tetanus toxin
injections. Data collected from one cohort may be used to inform the other, and may provide a
more complete picture without compromising the quality of 1H MRS or EEG recordings.
Nevertheless, despite the concerns raised here regarding the electrophysiology results, it
is still interesting to note that within the first 2-3 three weeks, when the signal attenuation was
not as severe, the CTL group still consistently demonstrated higher number of spike along with
larger variance as well compared to the TET group (Figure 4.7A-B). While this observation
should be interpreted with caution in the absence of additional validation studies, it could be
indicative of the surgical procedure itself is producing electrophysiological change in the rat
brain and the treatment with or without tetanus toxin acts as a potent modifier to how the rat
brain recovers from the insult. More studies that directly compare the surgery procedure with
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and without vehicle injection would be needed to truly determine the effect that the procedure
itself has on the electrophysiology.
While we were not able to replicate the electrophysiology with our new approach, we
may still interpret the 1H MRS metabolite data in context of the known IED behavior associated
with this animal model, which is progressive and sustained increase in IED frequency over time
(Barkmeier et al., 2012). The dynamic changes in metabolite levels over the course of the study
period in the TET group were impressive. A disproportionate number of these metabolite
changes were found in the anterior portions of the brain, coinciding with increased spiking
activity noted in the anterior electrodes relative to the posterior electrodes.

This anterior

dominant distribution of both significant metabolite changes and elevated spiking activity points
to a potential link between these two phenomena and may reflect downstream changes associated
with the upregulation of various plasticity markers noted by Barkmeier and colleagues
(Barkmeier et al., 2012) in this animal model.
At 4 months of age at the beginning of the study, these rats are well beyond their early
development phases and would generally be considered equivalent to humans at approximately
30 to 40 years of age (Sengupta, 2013). We further attempted to account for aging changes by
subtracting metabolite changes observed in a typically developing non-surgical cohort over the
same study period from the metabolite values of our treatment groups. It is, therefore, unlikely
that these metabolite changes are caused by developmental growth, maturation, or aging effects.
For example, taurine, an important modulator of synaptic plasticity (Flint, Liu, & Kriegstein,
1998), is found in high abundance in early brain development and decreases during development
to adult age (Tkáč, Rao, Georgieff, & Gruetter, 2003). However, here, we observe a significant
increase in taurine over time in the TET group, which may reflect its role as a neuromodulator
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and also potentially as a neuroprotectant against glutamate-induced neuronal excitotoxicity (Wu
et al., 2005), possibly in response to excessive tissue hyperexcitability associated with
epileptogenic activity. The subtraction of NCT metabolite changes over time from the treatment
groups only yielded a more extensive list of metabolites that changed significantly over time,
particularly in the TET cohort, but the metabolites significantly moderated by treatment group
membership (i.e. Gln, Tau, GPC+PCh, Cr+PCr) was quite robust and remained unchanged even
without subtraction of NCT group measurements from the measurements of TET and CTL
groups.
Also in the anterior regions of the rat brain, several metabolites showed different rates of
change over time moderated by the treatment group membership. The only metabolite to survive
FDR multiple comparison correction for this moderation effect by treatment group was
glutamine in the anterior right region of the rat brain. Glutamine levels tended to decrease over
time after an initial rise after surgical manipulation in TET animals while levels in CTL remain
relatively unchanged. Glutamine is converted from glutamate in glia by glutamine synthetase,
however the conversion between glutamate and glutamine and vice versa as part of the
glutamate-glutamine cycle is not necessarily in stoichiometric equivalence and depends heavily
on the alternative fates of glutamate (McKenna, 2007).

Since we observed a preferential

decrease in glutamine over time in the tetanus treated animals compared to the control animals in
the absence of a corresponding change in glutamate, the results would seem to indicate a
diversion of glutamate into alternative fates, such as the TCA cycle via conversion to αketoglutarate for energy production or GABA synthesis (McKenna, 2007). While GABA levels
cannot be measured reliably using PRESS on a 7T system, spectral editing techniques that allows
for the detection of GABA may provide additional insight.
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The increase in GPC+PCh and Cr+PCr lends credence toward the theory of glutamate
being diverted for energy generation.

Intriguingly, both of these metabolites were also

significantly increased in epileptic tissue in our HR-MAS 1H MRS ex vivo study, presented in
previously in Chapter 2.

GPC+PCh is typically a marker of membrane and phospholipid

turnover, but it is difficult to determine whether or not the turnover favors the anabolic or
catabolic side of membrane breakdown and synthesis pathways. In general, elevated GPC is
more indicative of membrane catabolism while elevated PCh is more indicative of membrane
synthesis (Stanley, 2002) and the contributions of both to the 1H MRS signal are approximately
equal in normal brain tissue (Miller et al., 1996). It is also likely that both mechanisms are at
work simultaneously, with the destruction of certain previously normal connections and the
creation of new connections elsewhere that serves to reinforce the likelihood of future
epileptiform activity. Cr+PCr are key players in high-energy phosphate metabolism. PCr serves
as a high-energy phosphate reservoir, and may donate the phosphate group to ADP to generate
high ATP be converted to creatine itself (Andres, Ducray, Schlattner, Wallimann, & Widmer,
2008). It is impossible to disentangle the relative contributions of Cr versus PCr to the Cr+PCr
signal, but taken together, an elevated Cr+PCr could signal an upregulation of high-energy
reserves to accommodate increased energy demand. Taurine, as mentioned previously may serve
as an important neuromodulator and relative increase in the tetanus treated animals may indicate
its role as a compensatory mechanism to attenuate the hyperexcitable tendencies associated with
epileptogenesis.
Despite the ambiguity of the electrophysiology results in this study, the 1H MRS study
still provided us with valuable clues on the changing energy demands associated with epilepsy
development and IED activity. Most interestingly, several key metabolites related to membrane
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plasticity and energy demand observed here were also found in our HR-MAS 1H MRS study of
human epileptic tissue and recapitulates many of the same themes of disturbed energy and
metabolism balance.

This study provides the evidence that non-invasive 1H MRS, when

combined with an animal model of epilepsy, can be a powerful tool to not only identify and
validate metabolite biomarkers for epilepsy, but also as an opportunity for understanding the
underlying biomolecular changes associated with epileptogenesis.
The availability of a well-characterized animal model of epilepsy that can parallel the
disorder in humans is extremely helpful for efficient drug testing and informing our mechanistic
understand of how epilepsy develops and persists in humans. Because of its flexibility, animal
models can also serve as a useful bridge for translating basic molecular findings at the organism
level and be used to predict treatment response in humans. While many different models of
epilepsy currently exist, they are used to study different aspects of epilepsy (Pitkänen et al.,
2005).

The neocortical tetanus toxin model in rats produces chronic, sustained IED with

relatively few seizures and is ideal for our goal of studying the role of IED in epileptogenesis.
Previous studies in our laboratory have shown that a distinct set of molecular changes
promoting plasticity takes place in this animal model (Barkmeier et al., 2012) and these changes
parallel what was seen in human epileptic tissues (Beaumont et al., 2012; Rakhade et al., 2007).
In Chapter 3, we demonstrated the ability of 1H MRS to identify a unique metabolite expression
profile that was highly predictive of epileptic tissue obtained from human subjects. Here, we
were able to show partial overlap in the metabolites associated with epileptogenesis in an animal
model in vivo and those associated with established epilepsy in human neocortical tissue samples
ex vivo. Specifically, these overlapping metabolites include relative increases in Cr+PCr as well
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as GPC or GPC+PCh in regions most affected by epileptiform changes, potentially reflecting a
state of increased energy demand as well as enhanced synaptic plasticity.
These metabolite markers have the potential to be developed into a non-invasive
biomarker of epilepsy, which would be extremely useful both for research and clinical
management. Having a sensitive and reliable non-invasive biomarker would allow for the
screening of early signs of epilepsy development in vulnerable individuals (e.g. traumatic brain
injuries), assist in the clinical management of existing epilepsy patients, and enable monitoring
of medication for therapeutic efficacy.

The latter application could open doors for the

development a new class of disease modifying medications that have the potential to stop the
development of epilepsy prior to seizure onset, unlike most of the ASDs available today, which
provide symptomatic management only.
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CHAPTER 5: DISCUSSION AND FUTURE DIRECTIONS
5.1 Discussion
Technological advances in the last hundred years have ushered in the era of modern
medicine, finally allowing individuals with epilepsy to be perceived as having a true neurological
condition with observable electrophysiological underpinnings.

Despite such remarkable

progress, epilepsy has stubbornly remained a disorder that can only be managed
symptomatically. Surgical resection of focal seizure onset regions is the only treatment option
that resembles a cure for the condition, and even so, long-term seizure freedom cannot be
guaranteed.
One of the biggest challenges currently facing epilepsy is the symptomatic nature by
which the disorder is diagnosed and managed. By the time they are diagnosed, epilepsy patients
usually have already suffered at least several episodes of seizure. This is akin to only treating
patients with potential myocardial infarctions after they have experienced an infarction. Given
the self-reinforcing nature of seizure activity in the brain, the truly ideal time for treatment would
be prior to the appearance of the first seizure episode. The development of a reliable yet noninvasive biomarker for epileptogenesis could dramatically change the way epilepsy is detected
and managed.
Such a biomarker would come with at least two very obvious benefits. First, this tool
would pave the way for the development of a new class of disease modifying pharmaceuticals
that can target the underlying etiologies. Even after such a drug has been developed, having
these non-invasive biomarkers would dramatically increase the efficiency and decrease the cost
of the necessary clinical trials required to bring the product to market (Engel et al., 2013). Such
a biomarker tool could help identify those most likely to develop epilepsy to participate in these
clinical trails and also act as surrogate markers of efficacy, providing early information on drug
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efficacy without having to use the delayed measure of seizure frequency as an indicator. Second,
a biomarker would enable the screening of vulnerable populations for early signs of
epileptogenesis. Those who are found have early signs of epileptogenesis are also the ones who
would benefit the most from the disease modifying drugs, which may be able to halt the
epileptogenic process before the patient even develops seizures.
Previous studies in our laboratory have consistently observed robust but localized
MAPK/CREB activations in regions of the brain most affected by epileptiform activity in the
form of IEDs (Barkmeier et al., 2012; Beaumont et al., 2012). The downstream effects of
MAPK/CREB dependent transcriptional activation are numerous and typically favor cell growth
and proliferation.

The downstream protein, macromolecule, and metabolic consequences

associated with MAPK/CREB activation may be used as biomarkers for epilepsy. We proposed
here, that 1H MRS might be a sufficiently sensitive technique for detecting these changes.
Besides accuracy and sensitivity, other features that are desirable in a biomarker tool for
epilepsy include: 1) applicable and useful for both research and clinical care, 2) non-invasive for
repeated follow up measurements and, 3) good spatial resolution for identification of the seizure
focus. One of the major advantages of 1H MRS is the ease by which the technique may be
adapted for in vitro, ex vivo, in vivo, and clinical use. Hypotheses generated in one experimental
modality may be tested in a parallel approach in a different modality. In vivo research and
clinical 1H MRS are also non-invasive. For the clinical side specifically, the technique uses
much of the same equipment and hardware as conventional MRI scans and may be incorporated
as an additional sequence for a patient who is already scheduled to receive a MRI. While the
spatial resolution of 1H MRS is not necessarily high compared to anatomical imaging, it is
currently capable of achieving nominal resolutions of around 1 cm3 (Chu et al., 2000; Maudsley
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et al., 2006). This spatial resolution is adequate for our proposed application and is on par with
the spatial resolution offered by subdural ECoG, typically at 1 cm2, and is also superior to the
resolution of scalp EEG, estimated to be around 10 cm2 (Tao et al., 2005).
One potential weakness of 1H MRS is its relative lack of sensitivity compared to more
invasive counterparts such as microdialysis, high-performance liquid chromatography (HPLC),
or even mass spectrometry, as it requires concentrations of at least 0.5 to 1 mmol/kgwet weight or
greater (Govindaraju et al., 2000) for reliable detection.

This is a significant change in

concentration for a well buffered organ, where concentration changes associated with
physiologic functions are on the scale of nM to µM. Nevertheless, and as reviewed in Chapter 1,
many 1H MRS studies in the past few decades have examined metabolite changes associated
with epilepsy, particularly in the temporal lobe epilepsies, with relatively consistent outcomes.
The results of our own studies here also demonstrate that 1H MRS has sufficient sensitivity to
detect metabolite changes associated with epilepsy. These are good indications that epilepsy
produces metabolite changes that are of a sufficient magnitude to be detected by 1H MRS.
5.2 Identification of epileptic metabolite profile using HR-MAS 1H MRS
Using HR-MAS 1H MRS on surgically resected human epileptic tissue was a natural
place to start the search for epileptic biomarkers, as it maximizes the likelihood that a useful
metabolite marker could be detected. The HR-MAS system, at 11.7T, is exquisitely sensitive to
small metabolite changes with well-resolved peaks, flat baseline, and ability to detect numerous
metabolites that cannot easily be detected or resolved in vivo. Its ability to analyze intact tissue
is also more advantageous than traditional chemical extraction procedures (e.g. perchloric acid
extraction), which can perturb the relative composition of compounds within the tissue. Also,
the study of epileptic tissue in patients with more established and intractable epilepsies, while not
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ideal for studying epileptogenesis itself, it is useful for identifying metabolites that are key
players in epilepsy and provide clues for the biochemical changes underlying the disorder.
Dynamic changes in those metabolites could also be important modulators of epileptogenesis as
well.
The most remarkable finding from this study is the identification of a unique metabolite
profile that is highly predictive of high and low spiking tissue samples. The optimized accuracy
of this predictive metabolite profile was 83% and these predictions can be made in a relatively
systematic and non-biased manner.

While direct comparisons cannot be made given the

uniqueness of this study, for perspective, the ability of 1H MRSI to correctly lateralize the side of
the affected temporal lobe in temporal lobe epilepsy is reported to be between 62 - 86%
(Capizzano et al., 2001; Cendes et al., 1997b). These prediction accuracies appear comparable,
but it can be argued that accurate classification of neocortical tissue samples both within and
across different patients, as done here, is more challenging and more informative than simple left
or right lateralization of the affected temporal lobes specifically in patients with temporal lobe
epilepsies.
Transcriptional microarray and histology data, all gathered as part of SBEP (Loeb, 2010),
provided this study the opportunity to further characterize these metabolite changes and their
associated metabolite changes. Correlational clustering studies done between genes that were
differentially expressed in high spiking samples and key metabolites revealed two major clusters
centered on the down-regulation of lactate and the up-regulation of Cr+PCr in high spiking
regions. Together, the two clusters provided hints of energy and metabolic disequilibrium in the
high spiking cortex. The differentially expressed genes associated with the lactate cluster were
also significantly enriched in genes participating in GPCR signaling and angiogenesis. The
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upregulation of genes associated with angiogenesis, and also validated by histology, was yet
another piece of evidence that pointed to a state of persistent energy imbalance in the tissue.
These findings suggest that energetic demand of the epileptic cortex outstrips production,
resulting in the activation of various compensatory mechanisms and utilization of alternative
energy sources. The enrichment of GPCR related genes, while not necessarily surprising given
the dramatic impact of recurrent electrical discharges on the epileptic neocortex, remain an
interesting topic for further study and may implicate potential new pharmaceutical candidates for
the treatment of epilepsy.
While this study revealed some interesting findings on the metabolite profile of human
epileptic tissue, there are several limitations that should be considered.

This study was

performed on a relatively small number of patients, thus limiting the number of unique samples
we had available for analysis. As a result, the predictive model was generated from and operated
on the same set of samples. While statistical approaches like leave-one-out cross-validation and
bootstrapping can be extremely helpful in characterizing how robust the predictive model is in
these situations, there is no substitute for true validation in a completely new dataset. Therefore,
one of the key next steps for this project would be the collection of a new dataset for validation
purposes. The ex vivo nature of this study, where we are studying tissues outside of their natural
environment (i.e. within a living organism), is also a major limitation. This study is extremely
useful as a first step to demonstrate that 1H MRS can detect metabolite differences unique to
epilepsy, but to truly translate these findings to human epilepsy for research or clinical purposes
would require further investigations in both animal models and human subjects in vivo.
Clearly, much more work would need to be done to apply the findings of this study
toward non-invasive clinical use. Nevertheless, the predictive metabolite profile identified here
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is a clear demonstration that 1H MRS is capable of discerning changes in focal metabolic
environments associated with persistent epileptiform activity. Using this metabolite profile, our
prediction model was able to make systematic and unbiased classification of tissue with good
accuracy. Transcriptional microarray and histology data collected in parallel also provided
useful insight into the events underlying the observed metabolic changes.
5.3 Identification of key metabolites changes in an animal model of IED
Applying 1H MRS to a longitudinal animal model of IED and epileptogenesis addressed
two very important questions from a biological perspective. First, it served as an important
follow-up to the HR-MAS 1H MRS ex vivo human tissue study by directly examining metabolite
changes associated with epileptogenesis and compared that with the profile found in our ex vivo
human tissue study for similarities and differences. Second, given the ambiguity over the role of
IED in epileptogenesis, this was an opportunity to study how changes in IED load over time may
lead to seizure generation and how that transition process may be characterized by changes in
metabolite levels. 1H MRS measurements can help disentangle the relationship between IED and
seizure development by addressing the following questions: a) are there any metabolites that are
strongly related to IED frequency and if so, b) are those metabolite changes consistent with
changes seen in established epilepsy. Presence of one or more common metabolites between
those associated with IED and those associated with epilepsy provide further proof that these two
electrophysiological phenomena are linked. The causal relationship between IEDs and seizures
may be partially inferred based on the temporal play out of these two phenomena (e.g. IEDs
preceding seizure activity or vice versa). A more complete determination of causal effects would
require directly manipulating of IED frequency itself and observing its impact on seizure
occurrence.

Attempts at those types of causal experiments have been made by both
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pharmacologic manipulations (Barkmeier et al., 2012) as well as by simple observations of the
relationship between changes in IED frequency and rate of seizure onset based on natural
variations in the experiment (White et al., 2010). Both studies have concluded that IEDs play an
important role in the generation of seizure activity.
While shortcomings in the experimental design, as discussed in depth in Chapter 3, may
have limited our interpretation of the longitudinal electrophysiology data collected from our in
vivo rat study and prevented this studying from providing satisfactory results to address the
second question, posed above, of how IEDs affect seizure development, the 1H MRS data
remained a valuable source of information and can be used to address the first question of
whether established epilepsy share common metabolite features with epileptogenesis.

A

reasonable case can also be made for the interpretation of 1H MRS data in the context of
historical electrophysiology information our laboratory collected previously on this animal
model.
The first interesting observation to emerge from this study was the difference in
metabolite dynamics over time between CTL and TET groups, concentrated in the anterior
portions of the rat brain, which also happened to coincide with the greatest number of IED
observed in our experimental EEGs.

Many more metabolites in TET showed significant

concentration changes over the study period, even after correcting for multiple comparisons (7
metabolites in TET versus 1 metabolite in CTL). This phenomenon could be a reflection of the
dramatic plasticity and remodeling taking place in epileptogenic regions of the brain.
Several metabolites also showed significantly different rates of change over time
depending on the treatment the animal received. As mentioned in Chapter 3, glutamine was the
only metabolite to survive multiple comparison correction and its preferential decrease in tetanus
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treated animals without a concurrent increase in glutamate levels suggested the possibility that
glutamate was being diverted to alternative fates, such as energy production. Despite not being
statistically significant after multiple comparison correction, increases in taurine, a
neuromodulator of plasticity, and GPC+PCh, an indicator of increased membrane turnover, point
to significant tissue remodeling within the cortex, which would presumably be an energetically
demanding process given the high cost of de novo membrane synthesis (Harris & Attwell, 2012).
This theory of increased energy demand was also corroborated by the preferential increase in
Cr+PCr levels, another key player in high-energy phosphate metabolism, although the change
was not statistically significant (p < 0.07).
Similar to the results of our ex vivo human tissue study, the metabolite changes over time
observed in this study, also reflected a state of energy and metabolism disequilibrium in epileptic
tissues. Changes seen in GPC+PCh and Cr+PCr, despite neither being statistically significant
after multiple comparisons correction in this study, very much parallels their involvement as
important predictors of epileptic in our ex vivo human study. While this overlap in metabolites
should be interpreted with caution as neither were statistically significant in a technical sense, it
is still a cause for optimism, considering differences in experimental design between the two
studies, with one being performed on the superficial layers of surgically excised human
neocortex and the other being performed on the full thickness cortex of an intact rat model.
While further studies are needed to validate these results, this study provides additional evidence
that 1H MRS may be a viable tool for identifying non-invasive biomarkers of epilepsy.
Beyond the obvious lack of high quality and reliable long term EEG recording from these
animals, this study has several other limitations worthy of consideration. Given the high level of
metabolite dynamics observed in the TET animal over the course of study, future studies could
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benefit from having more frequent MRS sessions than the every other week schedule we used for
this study to better capture the behavior of these dynamics. For this tetanus toxin animal model
in particular, our observation of control animals producing more interictal spikes than tetanus
treated animals was surprising and raises the important question of what the ideal control group
(e.g. vehicle injection versus sham surgery with no injection) should be and just what the impact
of the surgery itself has on the course of epilepsy development in these animal models. Epilepsy
itself is a disorder with a heterogeneous set of symptoms and semiologies. A truly useful
biomarker of epilepsy would have the ability to detect metabolite changes in several different
forms of the disorder.

Therefore, the study of other well-characterized animal models of

epilepsy could also be extremely informative.
5.4 Future directions
While many potential future studies have been suggested through the various chapters
and will not be repeated here, a few more general thoughts are included here for additional
consideration. It should be mentioned that a pilot study determining the usefulness of 1H MRS
in human epilepsy patients, discussed below, is currently underway.
5.4.1 Application of 1H MRS to human epileptic patients in vivo
Despite the importance of tissue and animal studies, a critical test for the viability of this
approach is to conduct them in humans. Applying 1H MRS to human epileptic patients in vivo is
an important step to determine whether or not this we have capability to detect these changes in a
clinical setting. As we are interested in studying how metabolites specifically in the cortex
change in response to disease onset and progression, high spatial resolution and whole brain
coverage are especially necessary and also difficult to obtain using conventional approaches as
there are no regions of interest that can be defined a priori. Continued development of the EPSI
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sequence (Posse et al., 1994), capable of full brain coverage and effective spatial resolution of
approximately 1 cm3, by Maudsley and colleagues in recent years has made this study a
possibility (Maudsley et al., 2006; Maudsley et al., 2009b).
Two studies thus far have used 1H EPSI in epilepsy patients (Maudsley et al., 2010;
Mueller et al., 2010) and have also shown widespread decreases in NAA level changes, similar
to what has been described in the literature. However, to the best of our knowledge, no studies
to date have tried to isolate the gray matter specific metabolite level changes in epilepsy patients
in vivo and attempted to correlate these changes to quantitative electrophysiology recorded from
ECoG obtained from the patients during the surgical workup to precisely identify the location of
their seizure focus. The aim of this in vivo human study would be to show how metabolite levels
as detected by 1H EPSI would differ between regions of high versus low IED rates in patients
with intractable epilepsy.
We are currently conducting a prospective study on 24 adult patients between the ages of
18 and 65 with the diagnosis of intractable epilepsy who are undergoing evaluation for epilepsy
surgery at the Comprehensive Epilepsy Program at Wayne State University/Detroit Medical
Center. Inclusion and exclusion criteria are provided in Supplementary Table 5.1.
Briefly, all patients will receive the 1H EPSI scan several weeks prior to their scheduled
surgery date. The scans are performed on a 3 Tesla Siemens Verio whole-body MR scanner with
a 12 channel 1H volume head coil. The scanning protocol consists of acquiring an initial set of
scout images, automatic and manual shimming, collecting the 3D EPSI data, followed by a set of
T1-weighted anatomic MRI images.
minutes.

The entire scanning process takes approximately 50
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The initial 3-plane scout image acquisition will be first obtained to ensure proper
alignment, patient cooperation, and image quality. The scout images will be used to prescribe
the in vivo 1H EPSI, with the slices oriented -15° above the AC-PC line. Shimming, for
improving B0 field homogeneity for maximal spectral resolution, will be done automatically with
additional manual optimization. The specifics of the 1H EPSI sequence are described elsewhere
(Ebel & Maudsley, 2003; Ebel, Soher, & Maudsley, 2001; Maudsley et al., 2009a).
Acquired spectroscopic data will be analyzed using the MIDAS software (Maudsley et
al., 2006), designed specifically for processing 1H EPSI data. To take full advantage of high
resolution whole brain ¹H MRS, we will co-register spectroscopic data with electrophysiology
data from intracranial electrodes using a combination of pre-implantation anatomical MRI, post
implantation CT, and intraoperative photographs. IED rates, as determined from three distinct
10 minute segments of awake intracranial EEG recordings, along with covariates such as age,
gender, and years of disorder, will be used to predict levels of NAA, Cr+PCr, and GPC+PCh in a
repeated measures type linear regression model. If IED dependent changes in metabolite levels
are seen, a logistic regression model similar to the one used in the ex vivo human tissue study can
be implement to predict whether a particular voxel or group of voxels could be epileptic in
nature.
A preliminary analysis of our 1H EPSI in two subjects who underwent temporal
lobectomies without long term ECoG recordings have been performed. In the absence of actual
electrophysiology, placement intracranial electrodes were simulated in this preliminary analysis
to cover portions of the superior and middle temporal lobe in both patients, bilaterally. These
simulated electrode locations are used to guide voxel extraction from the spectroscopic data for
analysis. In all, 121 unique voxels between 2 patients, with 55 voxels in the left temporal lobe
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and 66 voxels in the right temporal lobe were analyzed using repeated measures GLM, where we
tested for side to side differences in either NAA, Cr+PCr, or GPC+PCh (ipsilateral or
contralateral to affected temporal lobe). We failed to detect ipsilateral versus contralateral
differences in GPC+PCh and Cr+PCr in these two subjects, but a slight increase in NAA levels
(uncorrected p < 0.05) was observed in the ipsilateral cortex compared to the contralateral cortex.
Representative sample spectra from both the cortex of the ipsilateral and contralateral temporal
lobes are shown in Figure 5.1.
NAA
Cr+PCr
GPC
+ PCh

Ipsilateral

Contralateral

Figure 5.1 Representative spectra from bilateral temporal lobe neocortex in a representative
patient. Ipsilateral refers to the side of known seizure activity based on scalp EEG measures and
contralateral refers to a matching location on the opposite side. NAA levels appear elevated in
the ipsilateral side compared to the contralateral side.
While these metabolite findings need to be replicated and confirmed with the full study
sample, this preliminary analysis serves as a demonstration of feasibility. Based on the quality of
the data obtained from these two subjects, 1H EPSI appears to be capable of collecting spectra of
adequate quality in the neocortex for the analysis of NAA, Cr+PCr, and GPC+PCh in our
epilepsy patient population while its relatively high spatial resolution would facilitate successful
co-registrations to subdural ECoG data.
5.4.2 Exploring energetics with 31P and 13C spectroscopy
The results of our 1H MRS studies implicate, in multiple lines of evidence, that epileptic
tissues consistently exhibit signs of energy derangement, where the demand for energy appear to
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exceed that of supply and alternative energy sources are being recruited, based on inferences
made from other metabolites such as the relative decreases in lac and Gln. Because of the
overlap in resonances between Cr and PCr to form the combined Cr+PCr peak, it is impossible to
disambiguate the relative contributions Cr compared to PCr and therefore difficult to say if the
observed elevation in Cr+PCr is due to increases in Cr or PCr alone or due to simultaneous
increases in both, where each of those scenarios could lead to a different interpretation of the
results.

A similar issue applies to GPC+PCh, particularly in vivo, where GPC and PCh

resonances overlap but individually they are associated with different sides of the membrane
turnover equation (i.e. synthesis versus breakdown).
To improve our understanding of what is happening, especially in vivo, with Cr, PCr,
GPC, and PCh,

31

P MRS could be implemented as a supplementary technique, where those

individual metabolites, especially Cr and PCr can be easily discerned. GPC and PCh would be
incorporated into the peaks for phosphodiesters (PDE) and phosphomonoesters (PME),
respectively. Fortunately, interpretation of PDE and PME levels remains very similar to that of
GPC and PCh, where PDE are typically considered membrane breakdown components while
PME are considered membrane synthesis precursors (Stanley, 2002).
Our results of decreased Lac and Gln on 1H MRS led us to theorize that Lac and Glu may
have been diverted as alternative sources of energy. While we do not have a direct way of
testing that hypothesis using 1H MRS, 13C MRS studies may be a useful in this setting.

13

C MRS

is a well characterized and non-invasive way to measure metabolite synthesis rates and metabolic
flux (Boumezbeur et al., 2010; Shen & Rothman, 2002), although it is not a widely adopted
technique due to the need for hyper-polarization or enrichment of 13C isotopes. Nevertheless, if
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feasible, a 13C study could help elucidate the fates of both Lac and Glu and how they may relate
to the TCA cycle.
5.5 The future of MRS in epilepsy
MRS as a technique can be a very versatile for identifying changes in a variety of
compounds, across a variety of experimental environments. However, it can be made much
more powerful with the integration of various other experimental modalities, such as
electrophysiology, genomics, pharmacological manipulations, optogenetic manipulations,
dissection of animal models, and a variety of other molecular studies, as evidenced by the studies
presented in this dissertation. Much work still needs to be done to better identify and validate
biomarkers that can reflect the underlying mechanistic changes taking place in epilepsy, but 1H
MRS shows great promise.
The results of this project indicate that 1H MRS does have the ability to detect metabolite
differences between epileptic and non-epileptic regions and that our finds are suggestive of an
overlap in metabolite profile between established epilepsy cases and epileptogenesis in an animal
model. These studies are crucial first steps for demonstrating the potential of this technique for
non-invasive epilepsy biomarker identification. When applied appropriately, this is a technique
that has the potential to dramatically change how clinicians diagnose and manage epilepsy and
inform the direction of future ASD research efforts.
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APPENDIX A: LIST OF METABOLITES FITTED IN THIS PROJECT
Complete list of fitted metabolites for HR-MAS 1H MRS (CPMG) at 11.7T
1. Acetate
2. Alanine
3. Aspartate
4. Betaine
5. Carnitine
6. Choline
7. Citrate
8. Creatine plus phosphocreatine
9. GABA
10. Glutathione
11. Glycerophosphorylcholine
12. Glutamine
13. Glutamate
14. Glycine
15. myo-Inositol
16. Lactate
17. N-acetylaspartate
18. N-acetylaspartyl glutamic acid
19. Phosphorylcholine
20. Phosphorylethanolamine
21. Pyruvate
22. scyllo-Inositol
23. Succinate
24. Taurine
25. Simulated macromolecule at 1.67 ppm
26. Simulated macromolecule at 1.75 ppm
27. Simulated macromolecule at 1.40 ppm
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Complete list of fitted metabolites for 1H SVS MRS (PRESS) at 7T
1. Alanine
2. Aspartate
3. Cr+PCr
4. GPC+PCh
5. GABA
6. Glucose
7. Glutamine
8. Glutamate
9. Glutathione
10. myo-Inositol
11. Lactate
12. N-acetylaspartate
13. N-acetylaspartyl glutamic acid
14. scyllo-Inositol
15. Taurine
16. Simulated macromolecule at 1.3 ppm
17. Simulated macromolecule at 0.9 ppm
18. Simulated macromolecule at 2.0 ppm
19. Simulated macromolecule at 1.2 ppm
20. Simulated macromolecule at 1.4 ppm
21. Simulated macromolecule at 1.7 ppm
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APPENDIX B: SUPPLEMENTARY TABLE
Inclusion criteria

Exclusion criteria

1 Age 18 or older

1 Presence of metal implants; may be hazardous to patient
health or cause significant signal distortion

2 Patients with history of intractable epilepsy being evaluated
through the Comprehensive Epilepsy Program and Wayne
State University/Detroit Medical Center

2 Brain malformations that may confound identification of key
anatomical landmarks

3 Are planning on undergoing extraoperative subdural
intracranial EEG recordings as part of their presurgical
evaluation

3 Patient discomfort, anxiety, or inability to remain still during
duration of scan

4 Are willing to undergo an additional hour of MR scanning for
research purposes

Supplementary Table 5.1 Inclusion and exclusion criteria for patient recruitment in human
epilepsy study using whole brain 1H EPSI.
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Epilepsy is a serious neurological disorder that affects 1% percent of the global
population. Despite its status as one of the oldest neurological disorders known to man, its
mechanisms remain poorly understood. Available medications are not curative but provide
symptomatic management and do not work for well for more than 30 percent of patients.
Because it is nearly impossible to predict on an individual level who will eventually develop
epilepsy, it is also a disorder that can only be diagnosed after the patient has experienced
established seizure activity, eliminating any possibility of stopping the disorder in its prodromal
phase, before the patients are symptomatic.

Availability of a reliable and non-invasive

biomarker tool that can predict and identify the development of epilepsy would dramatically
change how the disorder is detected, monitored, managed, and treated. In this project, we tested
the potential of 1H MRS to provide metabolite biomarkers of epilepsy and epileptogenesis, both
in human neocortical tissue obtained from intractable epilepsy patients who underwent resective
surgery and also in a longitudinal rat model of epileptogenesis, using interictal epileptiform
discharges as a surrogate indicator of disease progression. Using 1H MRS, we found unique
metabolite differences that are highly predictive of epileptic and non-epileptic neocortex in
humans that also partially overlaps with findings from our rat model. These findings provide

104
evidence that 1H MRS is capable of identifying metabolite changes specific to epilepsy and may
lead to reliable and non-invasive biomarkers of epilepsy and epileptogenesis in the future.
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AUTOBIOGRAPHICAL STATEMENT
How is it that a few pools of ions across some semi-permeable membranes could generate
the electrical activities allowing us to see, breathe, think, laugh—when those same ions and
membranes can give us disorders like epilepsy?
In his own words, my father once said that he was born to be an engineer. He perceived
the world in a series of question. How is this made? How does it work? How can I use this to
make my own work better? From as far back as I could remember, he had always tried to foster
and encourage a similar mindset in me—ask questions, solve problems. A graduate of the
University of Michigan with a degree in Biomedical Engineering, and currently a student in the
MD/PhD program at Wayne State University, I am constantly mindful of the intersections
between science, medicine, knowledge, and applications.
I have been blessed with the opportunity to work on this project under the supervision of
Drs. Jeffrey Loeb and Jeffrey Stanley. This project has been an incredibly enriching experience,
in terms of my intellectual, academic, technical, and social development. This project has been
very unique in the sense that we attempted to apply technology to a real medical disorder in a
way that can have significant clinical impact, while continuing to learn more about fundamental
aspects of the disorder. Epilepsy is an incredibly interesting disorder to study, not only for its
complexities, but also for the tantalizing clues it provides for how our own brain functions.
Ideally, I would like to continue my future research work within neuroscience, perhaps
even in epilepsy. I am especially interested in learning more about the molecular, physiologic,
and electrophysiological factors underpinning behavior and cognitive function and how that
information may be in turn used to inform clinical understanding and management of neurologic
and psychiatric conditions.

